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Introductory remarks 
I have chosen for the presentation of my results a cumulative PhD Thesis. Two 
publications are discussed thereby; in one of them I have a shared co-authorship with 
Dr. rer. nat. Mandy Bodnar, and in the second one I am the fourth author. 
 
These publications are the following: 
Bodnar M*, Wang H*, Riedel T, Hintze S, Kato E, Fallah G, Gröger-Arndt H, 
Giniatullin R, Grohmann M, Hausmann R, Schmalzing G, Illes P, Rubini P (2011) 
Amino acid residues constituting the agonist binding site of the human P2X3 
receptor. J Biol Chem 286:2739-2749 (*Both authors contributed equally to this 
work). 
Hausmann R, Bodnar M, Woltersdorf R, Wang H, Fuchs M, Messemer N, Qin Y, 
Gunther J, Riedel T, Grohmann M, Nieber K, Schmalzing G, Rubini P, Illes P 
(2012) ATP binding site mutagenesis reveals different subunit stoichiometry of 
functional P2X2/3 and P2X2/6 receptors. J Biol Chem 287:13930-13943. 
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Referat 
Homotrimeric P2X3 and heteromeric P2X2/3 receptors are present in sensory 
ganglia and participate in pain perception. In order to develop pharmacological 
antagonists for these receptors, it is important to clarify which amino acid (AA) 
residues constitute the agonist binding pouch as well as to learn the stoichiometry of 
the receptor subunits forming a heteromeric receptor. We expressed the homomeric 
human (h)P2X3 receptor or its mutants in HEK293 cells and measured the ATP-
induced responses by the whole-cell patch-clamp method. For the binding-site 
mutants, all conserved and some non-conserved AAs in the four nucleotide binding 
segments (NBSs) of the P2X3 subunit were sequentially replaced by alanine. 
Especially the positively charged AAs Lys and Arg appeared to be of critical 
importance for the agonist effects. We concluded that groups of AAs organized in 
NBSs rather than individual amino acids appear to be responsible for agonist binding 
at the P2X3 receptor. These NBSs are located at the interface of the three subunits 
forming a functional receptor. We were also interested to find out, whether two 
heteromeric receptors (P2X2/3 and P2X2/6), where P2X2 combines with two different 
partners, have an obligatory subunit stoichiometry of 1:2 or whether the subunit 
stoichiometry may be variable. For this purpose we used non-functional P2X2, P2X3 
and P2X6 subunit-mutants to investigate the composition of heteromeric P2X2/3 and 
P2X2/6 receptors. The subunit stoichiometry of P2X2/3 and P2X2/6 was found to be 
1:2 and 2:1, respectively. Thus, recognitions sites between P2X2 and its partners 
rather than random association may govern the subunit compositions of the receptor 
trimers. 
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I. Introduction 
Pain as a sensory quality 
   The Taxonomy Committee of the International Association for the Study of Pain 
(IASP) describes pain as being „An unpleasant sensory and emotional experience 
associated with actual or potential tissue damage, or described in terms of such 
damage” (Mac-Farlane et al., 1997). Painful sensations may be classified according 
to their duration as acute or chronic. Acute pain has an important signalling function 
in order to avoid tissue damage (e.g. by triggering a spinal reflex to remove a finger 
from the hot stove plate or by forcing an individual to immobilize his injured 
extremity). However, chronic pain may become a self-containing illness, inducing 
unnecessary hardship for a patient (e.g. cancer pain). A second possibility to classify 
pain is according to its source (superficial or deep). Injury to the skin causes 
superficial pain, whereas ischemia of the heart or overt distension of hollow visceral 
organs produces deep pain. A special type of chronic pain, termed neuropathic, will 
be the primary subject of this Thesis.  
   Neuropathic pain can be defined as a condition resulting from non-inflammatory 
dysfunction of the peripheral (PNS) or central nervous system (CNS), without 
nociceptor stimulation or trauma. The development of chronic pain following 
peripheral nerve injury has been attributed to the occurrence of three different 
processes in the spinal cord: increased excitability, decreased inhibition and 
structural reorganization of the cells (Woolf and Doubell, 1994). The classic 
symptoms are (1) stimulus-independent pain, (2) hyperalgesia (increased pain 
response to a suprathreshold noxious stimulus), and (3) allodynia (pain elicited by a 
normally non-noxious, e.g. tactile stimulus) (Woolf and Mannion, 1999). Neuropathic 
pain can result from peripheral nerve trauma (deafferentation, amputation), infection 
(post-herpetic neuralgia), human immunodeficiency syndrome-associated neuralgia, 
or metabolic disturbance (diabetic pain). An excruciating, usually unilateral type of 
neuropathic pain occurs in the distribution of the trigeminal nerves (trigeminal 
neuralgia); it is triggered by e.g. a light touch at the cheek. A common characteristic 
of neuropathic pain states is their relative insensitivity to treatment by opioids. In 
general, neuropathic pain is rather resistant to pharmacological therapy with the 
exception of trigeminal neuralgia which is treated by anticonvulsants 
(carbamazepine, sodium valproate, phenytoin) blocking voltage-sensitive sodium 
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channels. In conclusion, there is a great need for drugs to treat neuropathic pain 
efficiently and without tolerable side-effects. 
 
Neuronal circuitry for pain processing and sensation in the PNS and CNS 
   The cell bodies of primary sensory neurons are located in the trigeminal ganglia 
(TG) as well as dorsal root ganglia (DRG), and innervate the head and the body, 
respectively (Hunt and Mantyh, 2001; Mantyh et al., 2002; Todd, 2010). 
 
Abb. 1.  Nociception. Normal pain signalling in the body is transmitted to the spinal 
cord dorsal horn through nociceptors. Primary afferent terminals project onto pain 
projection neurons in laminae I, IV and V in the spinal cord dorsal horn. The cell 
bodies of primary afferent neurons are situated in the dorsal root ganglia (DRG) and 
are classified into large and small types. C and Aδ fibres have small cell bodies, 
whereas faster-conducting Aβ fibres have larger cell bodies. Pain signalling to 
supraspinal targets is via ipsilateral or contralateral ascending fibre bundles, the latter 
ones forming e.g. the spinothalamic tract (Milligan and Watkins, 2009; for more 
detailed explanation see text).  
 
   Nociceptive small-sized TG and DRG neurons are the origin of thin, unmyelinated 
C fibres, whereas medium-sized sensory neurons with a similar pain-sensing function 
send myelinated Aδ fibres to the periphery. Of the whole spectrum of primary afferent 
nerves, larger-diameter, myelinated fibre-types known as Aβ fibres are low threshold 
mechanoreceptors, and a group of C- and Aδ-fibres are thermoreceptive. Nociceptors 
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have the main function to detect and convert environmental stimuli that are perceived 
as harmful into electrochemical signals transmitted to the CNS (Mantyh et al., 2002).  
   Thus, TG and DRG neurons are pseudounipolar, by innervating with their longer 
peripheral processes the skin and visceral organs, while their central, shorter 
processes project to the dorsal horn of the spinal cord. In general, myelinated low-
threshold mechanoreceptive afferents arborize in an area extending from lamina II to 
V); nociceptive and thermoreceptive Aδ and C afferents innervate lamina I and most 
of lamina II (Todd, 2010). Lamina II consists almost exclusively of interneurons, 
which establish contact with the lamina I output neurons whose projections ascend at 
the contralateral side of the spinal cord to higher areas of the brain. Main supraspinal 
targets for lamina I projection neurons include the caudal ventrolateral medulla, the 
nucleus of the solitary tract, the periaqueductal grey matter and certain nuclei of the 
thalamus (Gauriau and Bernard, 2004). The nucleus ventralis posterior thalami sends 
further fibre tracts to the parietal and frontal lobes of the cerebral cortex, where the 
localization of painful stimuli within the organism takes place and these stimuli 
become associated with the subjective attribute of ‘unpleasant’ sensory information. 
Eventually, serotonergic and noradrenergic axons descend from the raphe nuclei and 
nucleus locus coeruleus, respectively, to the spinal cord and terminate diffusely 
throughout the dorsal horn (Zoli et al., 1999). Another descending pathway consists 
of GABAergic axons from the rostral ventromedial medulla that synapse with lamina 
II interneurons (Kato et al., 2006). Thus, these interneurons synapse with pain-
sensing sensory neurons from the periphery, pain-modulating pathways from higher 
brain areas, and with neighbouring interneurons, thereby integrating multiple 
information before transmitting it to the lamina I output neurons. 
   It has been already mentioned that chronic pain is a deleterious condition causing 
unnecessary suffering to the individual. Hyperalgesia/allodynia as symptoms of 
chronic pain stages can result from a number of different modifications leading to an 
increased responsiveness and stronger output from lamina I nociceptive projection 
neurons (Larsson and Broman, 2011). A well-established mechanism of central 
sensitization is modification of synaptic strength in the superficial dorsal horn. Intense 
electrical or natural noxious stimulation induce potentiation of C-fibre synapses in the 
dorsal horn (Drdla and Sandkühler, 2008), similar to the NMDA receptor-dependent 
long-term potentiation (LTP) evident in glutamatergic synapses also in other parts of 
the CNS (Kessel and Malinow, 2009).  
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Transformation of thermal, mechanical and chemical stimuli into electrical 
activity by nociceptors; nociceptor-targeted therapeutic approaches 
   Most C fibre terminals are polymodal nociceptors and respond to all forms of 
noxious stimulation (thermal, mechanical and chemical), albeit with various degrees 
of sensitivity. They are endowed with a whole range of receptors, of which transient 
receptor potential channels (TRPs) and acid-sensing ion channels (ASICs) have an 
eminent significance.  
 
Abb. 2.  Detection by sensory neurons of noxious stimuli produced by 
damaged or inflamed cells. Nociceptors use several types of receptors to detect 
and transmit signals about noxious stimuli that are produced after acute or chronic 
cell injury. VR1, TRPV1 receptor; ET, endothelin; ETAR, endothelin-A receptor; 
DRASIC, dorsal root acid sensing ion channel, EP, prostaglandin receptor; NGF, 
nerve growth factor; TrkA, tyrosine kinase receptor. (Mantyh et al., 2002; for further 
details see text). 
 
TRP ion channels are important for vision, olfaction, taste, mechanosensation, 
osmoregulation and thermosensation (Clapham, 2003; Patapoutian et al., 2009). The 
role of TRP channels in pain and thermosensation was first suggested by the finding 
that mammalian transient receptor potential vanilloid 1 (TRPV1) is activated by 
noxious heat, extracellular protons, and capsaicin the irritating ingredient of chilli 
peppers (Caterina et al., 1997). Six of the 28 TRP channels from the three distinc 
subclasses are activated by temperature (TRPV1-4, TRPM8, TRPA1) and are 
expressed in sensory neurons or in skin keratinocyte cells, which are peripheral 
targets of these nerves (Dhaka et al., 2006). The heat-sensitive TRPV1 and TRPA1 
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are co-localized in a subgroup of DRG and TG neurons; TRPM8 is expressed in 
another subgroup of sensory neurons that respond to innocuous cold temperatures 
(Papatopoutian et al., 2009). The protein sequences of the TRPs contain six putative 
transmembrane helices S1-S6 and a putative pore region between S5 and S6; they 
represent subunits of a tetrameric channel. The opening of TRPs allows the non-
selective passage of cations and thereby causes depolarization and the generation of 
conducted action potentials in C fibres.  
   ASICs are cationic channels that are directly gated by extracellular protons. They 
belong to the epithelial sodium channel superfamily (Deval et al., 2010). Each ASIC 
subunit (ASIC1-4) has two hydrophobic transmembrane domains, flanking a large 
extracellular loop. Resolution of the crystal structure of the chicken ASIC1 channel 
has shown that three subunits are necessary to form a functional channel (Jasti et al., 
2007). ASIC currents activate transiently upon extracellular acidification, the 
activation threshold, pH sensitivity and current kinetics depending on the subunit 
composition of the channel. Among ASICs, ASIC1 and ASIC3 are the most sensitive 
to protons, being activated by very small acidification. Conversely, ASIC2 currents 
are activated by more pronounced acidification (Deval et al., 2010).  
   Experimental evidence for the existence of acid-activated ion channels on sensory 
neurons isolated from DRG and TG has been provided as early as 1980 (Krishtal and 
Pidoplichko, 1980). In the meantime it has been documented that ASICs are involved 
in cutaneous and deep somatic pain, visceral pain, and heart and lung nociception 
(Wemmie et al., 2006). In addition the distribution of ASICs and TRPV1 appeared to 
exhibit very littler overlap in rat DRG, indicating complementary distribution and 
function (Molliver et al., 2005). 
   In addition to these two groups of important pain-sensing receptors, autacoids such 
as prostaglandins (Sawynok, 2003), and opioids (Fields, 2004; Cahill et al., 2006) as 
well as non-opioid peptides (e.g. bradykinin; Campos et al., 2006) may also modulate 
nociceptor function at the C-fibre terminals themselves. Receptors for these 
compounds are supposed to be associated with chronic pain states, and become up-
regulated during inflammation. It is quite clear, however, that the primary site of 
action of opioids is in the CNS and that of prostaglandins in the periphery. 
Nevertheless, opioid effects in the periphery and prostaglandin effects at spinal sites 
have also been documented (Zhang et al., 2004; Zeilhofer and Brune, 2006). 
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   All these channels and receptors are possible targets of pain therapy, although 
opioids and non-steroidal inflammatory drugs (NSAIDs) still remain the prototypic 
analgesics. NSAIDs are classic blockers of prostaglandin synthesis, with no 
selectivity for any of the cyclooxygenase subtypes (COX-1 or COX-2). In contrast, 
specific COX-2 inhibitors were originally supposed to be devoid of the side effects of 
NSAIDs exhibiting inherent gastrointestinal and renal toxicity. However, later it was 
observed that COX-2 inhibitors are cardiovascular risk factors, a finding which 
seriously limited their therapeutic applicability. More recently, new analgesic targets 
are emerging such as various types of voltage-sensitive sodium channels (Dib-Hajj et 
al., 2007; Liu and Wood, 2011). Individual isoforms of voltage-gated sodium channels 
have been linked to particular types of pain. Nav1.7 is a useful target for ameliorating 
acute mechanical pain and inflammatory pain. Strong evidence suggests that 
selective blockers for Nav1.9 could be used to treat inflammatory pain and blockers 
for Nav1.8 could have clinical benefit for visceral pain. 
 
Release mechanisms for nucleotides and their fate in the extracellular space 
   It has been suggested in the early seventies of the last century that the purine 
nucleotide ATP is a transmitter of the enteric nervous system (Burnstock et al., 
1970). Later on, excitatory junction potentials in the vas deferens were found to be 
due to ATP released as a co-transmitter together with noradrenaline (Burnstock and 
Verkhratsky, 2010). According to the present stage of our knowledge extracellular 
ATP is an almost general signalling molecule in the CNS and PNS involved in 
neuronal degeneration, central control of autonomic functions, neural-glial 
interactions, control of vessel tone, sensory transduction and the physiology of 
special senses (Burnstock, 2006). 
   In addition to the exocytotic secretion of ATP from nerve terminals and probably 
also astrocytes (Hamilton and Attwell, 2010), stimulation of astrocytes by 
pharmacological means as well as by mechanical or osmotic stimulation may release 
ATP by four alternative mechanisms (Illes and Alexandre, 2004). Firstly, by ATP-
binding cassette (ABC) proteins, such as the multidrug resistance-associated protein 
(Ballerini et al., 2002); secondly by connexin hemichannels providing the substrate 
for gap junction formation (Cotrina et al., 2000); and thirdly, by osmolytic transporters 
linked to cation channels (Darby et al., 2003). Eventually, ATP and more generally 
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speaking nucleotides may leave injured cells by passing their cell membranes 
towards the extracellular space. 
   ATP and other nucleotides act after their release at membrane localized receptors 
(see below). Their effect is terminated by rapid enzymatic degradation by ecto-
nucleotidases, which are important, because ATP metabolites (ADP, adenosine) act 
as physiological ligands for various purinergic receptors. Thus, the ecto-
nucleotidases not only control the life-time of nucleotides but by degrading or 
interconverting the originally released ligands, they also produce agonists for 
additional P2 and P1 receptors (Zimmermann and Braun, 1999). The ecto-
nucleotidase families consist of nucleoside triphosphate diphosphohydrolase 
(NTPDase), nucleotide pyrophosphatase (NPP), alkaline phosphatase, and 5’-
nucleotidase (Abbracchio et al., 2009).  
 
Nucleotide receptor-types 
   Burnstock suggested, based on purely pharmacological conclusions (rank order of 
agonist potencies and preferential antagonists), that P2 receptors may be classified 
into the P1 (sensitive to adenosine) and P2 (sensitive to ATP) types. Later he came 
up with the proposal that the P2 receptors belong to two major classes: a P2X family 
of ligand-gated ion channels and a P2Y family of G protein-coupled receptors 
(Abbracchio and Burnstock, 1994). This original suggestion became widely accepted 
after the cloning of all known P2 receptor types (North, 2002; Khakh et al., 2001; 
Abbracchio et al., 2006). 
   P2X receptor-channels form a family of seven subunits, referred to as P2X1 
through P2X7 (Khakh and North, 2006). The subunits consist of two transmembrane 
domains, a large extracellular loop containing the ATP binding site, as well as 
intracellular N- and C-terminal tails. Biochemical evidence indicates that both 
homomeric and heteromeric receptors occur as stable trimers (Nicke et al., 1998). In 
fact, heteromultimeric assemblies of two subunits of the composition P2X1/2, 
P2X1/4, P2X1/5, P2X2/3, P2X2/6 and P2X4/6 were also described (Coddou et al., 
2011). These receptors combined the biophysical and pharmacological properties of 
the original subunits. Co-immunoprecipitation experiments with epitope-tagged 
subunits demonstrated that only P2X6 was unable to form homooligomers and P2X7 
was the only exception of constituting heterooligomeric complexes (Torres et al., 
1999).  
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   Neuronal P2X receptors in the CNS appear to belong mostly to the P2X2, P2X4 or 
P2X4/6 types (Illes and Alexandre, 2004). The neuronal localization of P2X7 
receptor-channels is still a matter of debate, although it is quite clear that they are 
situated at astrocytes, oligodendrocytes and microglial cells in great abundance 
(Sperlagh et al., 2006; Illes et al., 2012). These receptors change their ion selectivity 
during longer-lasting exposure to ATP. Recently neuronal P2X2, P2X2/3 and P2X4 
receptor-channels were also found to progressively dilate during prolonged or 
repetitive ATP applications (Khakh et al., 1999). It was reported that in addition to 
larger cations also bulky fluorescent dyes (e.g. Yo-Pro-1) may enter the cell interior 
(Pelegrin and Surprenant, 2006). However, the suggestion that not the dilation of the 
receptor-channel itself but rather the coupling of P2X7 receptors to pannexin-1 
channels accounts for the cellular uptake of these molecules, has recently been 
questioned. 
   P2Y receptor proteins show the typical features of G protein-coupled receptors 
(GPCRs) (Abbracchio et al., 2006; Köles et al., 2009). They have an extracellular N 
terminus containing several potential glycosylation sites, seven transmembrane (TM) 
domains and an intracellular C terminus that contains several consensus 
binding/phophorylation sites for protein kinases. Some positively charged residues in 
TM domains 3, 6 and 7 seem to be crucial for receptors activation by agonists. 
   So far the P2Y family comprises of eight cloned and functionally defined 
mammalian subtypes (P2Y1,2,4,6,11,12,13,14); their pharmacological profiles and 
preferences for coupling to heterotrimeric G protein-subtypes are different. The 
original idea was that a GPCR is a monomeric transmembrane protein, which upon 
ligand binding interacts with a heterotrimeric G protein and, in consequence, initiates 
events characteristic for receptor activation (Köles et al., 2008). However, this view 
was revised, as a growing body of evidence indicated that GPCRs exist as oligomeric 
complexes. Combinations of A1 adenosine receptors with P2Y1 or P2Y2 nucleotide 
receptors were described, and similarly P2Y1/P2Y11 and P2Y4/P2Y6 receptors were 
also shown to be exist in close physical association. 
 
ATP-sensitive P2 receptors and pain sensation 
   In sensory ganglia, all seven cloned mammalian P2X receptors are present (Chizh 
and Illes, 2000; Wirkner et al., 2007). Six of them (P2X1-6) were detected with 
distinct distribution patterns in primary afferent neurons of the rat by means of 
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immunohistochemistry and in situ hybridization. In DRG neurons, P2X2 and P2X3 
receptor mRNA and protein were expressed at comparably high magnitude, while the 
other subtypes were expressed at much lower quantities.  
   Nociceptive C-fibre neurons are comprised of both peptidergic (endowed with 
receptor tyrosine kinase [TrkA] for nerve growth factor [NGF]) and non-peptidergic 
neurons (lacking TrkA). A subpopulation of non-peptidergic C-fibre neurons express 
the receptor complex for glial cell-derived neurotrophic factor (GDNF) also labelled by 
isolectin B4 from Griffonia simplicifolia (Molliver et al., 1997). The majority of P2X3-
positive neurons belongs to the GDNF-sensitive population and expresses TRPV1 
receptor-channels (Wirkner et al., 2007).  
   ATP and most of its structural agonists evoke rapidly desensitizing inward currents 
in acutely dissociated rat DRG neurons possessing homomeric P2X3 receptors 
(Chen et al., 1995). α,β-methylene ATP (α,β-meATP) activates these receptors with 
a considerable selectivity over all other P2X-types except P2X1 and the heteromeric 
P2X2/3. Indeed, in rat nodose neurons, P2X2/3 receptors predominate, where α,β-
meATP causes slowly desensitizing currents (Lewis et al., 1995). It is assumed that 
both receptor types are situated at the peripheral terminals of sensory neurons and 
respond to ATP released by chronic noxious tissue damage. In fact, exogenously 
applied ATP induces acute pain in humans and animals, which is inhibited by P2 
receptor antagonists, but endogenous ATP does not appear to be involved in acute 
thermal and mechanical pain, as these responses were unchanged in P2X3-
knockout mice (Cockayne et al., 2000; Kennedy, 2005). More recent studies are, 
however, consistent with a role of P2X3 receptors in the pain associated with chronic 
inflammation and neuronal injury (Donnelly-Roberts et al., 2008). Gene knockout 
methods, antisense oligonucleotides and small interfering RNA (siRNA) technologies, 
as well as a selective P2X3 antagonist uniformly support this assumption. Thus, in 
contrast to acute pain, ATP-gated cationic channels of the P2X3- and P2X2/3-types 
may contribute to pain sensation in inflammatory/neuropathic pain as well as 
migraine, and visceral/cancer pain (Wirkner et al., 2007). 
   In addition to the peripheral terminals and cell bodies of sensory neurons, P2X3 
receptors are also situated at their central terminals in the spinal cord dorsal horn. 
ATP was found to increase the electrophysiologically measured release of glutamate 
from DRG nerve terminals in lamina II of the spinal cord (Nakatsuka et al., 2003). The 
increase was transient and inhibited by P2 receptor antagonists indicating the 
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involvement of P2X3 receptors. In partial agreement with these results, in the 
projection field of Aδ fibres in lamina V, ATP and α,β-meATP caused long-lasting 
increase in glutamate release, probably mediated by other subtypes of P2X receptors 
(Nakatsuka and Gu, 2001).  
   Whereas P2X3 receptors are mostly expressed at small DRG neurons, P2Y 
receptors appear to be equally expressed in small, large and medium-sized sensory 
neurons (Gerevich and Illes, 2004). When the receptor protein was identified with 
immunohistochemistry, P2Y1 receptors were identified on TRPV1- and P2X3-bearing 
small diameter neurons of the rat DRG (Gerevich et al., 2004). The activation of P2Y1 
receptors by ADP or its structural analogue ADP-β-S inhibited N-type Ca2+ channels, 
with no effect on any other type of Ca2+ channel. The effects of ADP-β-S were 
abolished by P2Y1-selective antagonists. Finally, intrathecally applied ADP-β-S 
prolonged the nociceptive threshold in the tail-flick test, indicating spinally induced 
analgesia. It was suggested that while spinal P2X3 receptors increase the release of 
glutamate onto lamina II neurons, P2Y1 receptors have an opposite effect and are 
thereby analgesic. 
   We began to understand the role of ATP in neuropathic pain, when it was 
discovered that P2X4 receptors are intimately involved in tactile allodynia and 
hyperalgesia accompanying this pain state (Burnstock et al., 2011). P2X4 receptors 
facilitate the release of brain-derived neurotrophic factor (BDNF) from microglia in the 
spinal cord and cause a depolarizing shift in the anion reversal potential of spinal 
lamina I neurons that invert the polarity of current activated by the previously 
inhibitory transmitter GABA (Coull et al., 2005). Thus, the activity of the lamina I 
output neurons critically involved in the transmission of painful information to higher 
brain centres is facilitated. P2X7 receptors utilize another transduction pathway to 
cause pain (Burnstock et al., 2011). They increase the release of proinflammatory 
interleukin-1β and PGE2 from macrophages and microglia, sensitizing nociceptors in 
peripheral tissues or pain-transmitting neurons in the CNS (Clark et al., 2010). 
Astrocytes are also key players in chronic pain mechanisms secreting the classic 
immune signals: cytokines and chemokines (Milligan and Watkins, 2009).  
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II. Scientific background and aims of my thesis 
ATP binding-sites of P2X3 receptors; subunit composition of P2X2/3 and 
P2X2/6 heteromeric receptors 
   My thesis is based on two publications which I authored and co-authored, 
respectively during a one year stay in Leipzig. Because the specific questions 
investigated in them have been described in a detailed manner, and will be 
presented in the enclosed publications, I will give only an overall summary both of the 
scientific background and the discussion of the data obtained. All references to the 
relevant literature can be found in these publications. 
   Our first paper deals with the ATP binding site of homomeric P2X3 receptors. The 
following evidence from the scientific literature supplied convincing evidence for the 
three subunit composition of all P2X receptors: (1) Single channel analysis of P2X 
receptor currents indicated 2-3 sequential binding steps; (2) The kinetic behaviour of 
P2X receptor currents was simulated with an allosteric model describing channel 
opening in the di- or tri-liganded state; (3) Atomic force microscopy provided 
evidence for three receptor subunits; (4) Fluorescence energy transfer and electron 
microscopy supplied a rough structure of three interacting subunits; (5) The crystal 
structure of a zebrafish P2X4 receptor mutant confirmed the existence of a trimeric 
subunit composition.  
   For many years, knowledge on the amino acid (AA) residues possibly involved in 
agonist and antagonist binding, allosteric modulation, desensitization and channel-
gating of P2X receptors was derived from mutagenesis studies (replacement of the 
potentially relevant amino acids [AAs] usually by Ala or Cys). These studies uniformly 
suggested that at the agonist-binding site negatively charged phosphate groups of 
ATP occupy some positively charged AAs, specifically Lys or Arg in the extracellular 
loop of the receptor. Whereas originally it was assumed that each P2X subunit 
contains one individual binding site for ATP, it became soon clear that binding 
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probably occurs at the interface between two neighbouring subunits. The Leipzig 
group concluded on the basis of theoretical considerations and a survey of the 
relevant literature that conserved AAs organized in four clusters (termed nucleotide 
binding segments (NBS) are important for ATP binding. 
   Our second paper dealt with the subunit composition of two heteromeric P2X 
receptors (P2X2/3, P2X2/6) containing as one of the constituents P2X2. As 
mentioned previously, P2X2/3 receptors occur in sensory neurons and respond to 
ATP (or α,β-meATP) with slowly desensitizing currents. P2X6 receptors are an 
interesting member of the P2X family in that homomeric P2X6 do not express at the 
plasma membrane. However, the combination with P2X2 enables P2X6 to traffick 
and insert into the plasma membrane, although the potency of ATP at homomeric 
P2X2 is higher than at heteromeric P2X2/6. In addition, P2X6 acts as a modulatory 
unit by changing the functional properties of P2X2. 
   The subunit stoichiometry of P2X2/3 was found to be 1:2, but there are no 
comparable data available for P2X2/6. In a detailed investigation, two homologous 
AAs participating in agonist binding were replaced individually with Ala to yield 
inactive mutants of P2X2 and P2X3 subunits; combination of the mutant P2X3 with 
wild-type (wt) P2X2 resulted in non-functional receptors, whereas the opposite 
combination was fully active. Unfortunately, there were no accompanying 
biochemical data presented to confirm that the functionally silent AA mutants of P2X2 
and P2X3 and their compositions with their wt counterparts still exhibited undisturbed 
trafficking behaviour and were expressed at the cell surface. 
 
The aims of the present work 
   Our aims were twofold: 
1. Do certain individual (conserved or non-conserved) AAs at the supposed ATP 
binding sites of the human (h)P2X3 receptor determine its affinity to agonists 
or are the complete NBSs a pre-requisite for an indisturbed receptor function? 
2. Does the subunit stoichiometry of hP2X2/6 conform with that of hP2X2/3, or in 
other words does 1 P2X2 subunit associate with two P2X6 subunits or is the 
opposite combination valid? 
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Homomeric P2X3 receptors are present in sensory ganglia
and participate in pain perception. Amino acid (AA) residues
were replaced in the four supposed nucleotide binding seg-
ments (NBSs) of the human (h) P2X3 receptor by alanine, and
these mutants were expressed in HEK293 cells and Xenopus
laevis oocytes. Patch clamp and two-electrode voltage clamp
measurements as well as the Ca2 imaging technique were
used to compare the concentration-response curves of the se-
lective P2X1,3 agonist ,-methylene ATP obtained at the
wild-type P2X3 receptor and its NBS mutants. Within these
NBSs, certain Gly (Gly-66), Lys (Lys-63, Lys-176, Lys-284, Lys-
299), Asn (Asn-177, Asn-279), Arg (Arg-281, Arg-295), and
Thr (Thr-172) residues were of great importance for a full ago-
nist response. However, the replacement of further AAs in the
NBSs by Ala also appeared to modify the amplitude of the cur-
rent and/or [Ca2]i responses, although sometimes to a minor
degree. The agonist potency decrease was additive after the
simultaneous replacement of two adjacent AAs by Ala (K65A/
G66A, F171A/T172A, N279A/F280A, F280A/R281A) but was
not altered after Ala substitution of two non-adjacent AAs
within the same NBS (F171A/N177A). SDS-PAGE in the Cy5
cell surface-labeled form demonstrated that the mutants ap-
peared at the cell surface in oocytes. Thus, groups of AAs orga-
nized in NBSs rather than individual amino acids appear to be
responsible for agonist binding at the hP2X3 receptor. These
NBSs are located at the interface of the three subunits forming
a functional receptor.
ATP-gated, cation-permeable P2X receptor channels form
a family of seven subunits, referred to as P2X1 through P2X7
(1). The subunits consist of two transmembrane domains, a
large extracellular loop containing the ATP binding site, as
well as intracellular N- and C-terminal tails. Biochemical evi-
dence indicates that both homomeric and heteromeric recep-
tors occur as stable trimers (2–4).
Mutagenesis studies at homomeric P2X receptors uni-
formly suggested that the negatively charged phosphate
groups of ATP occupy some positively charged amino acids
(AAs),4 specifically Lys or Arg, in the extracellular loop of the
receptor (5–7). Moreover, aromatic Phe residues were as-
sumed to be associated with binding the adenine ring of ATP
(8). Molecular models were generated on the basis of these
studies, under the assumption that each subunit of the P2X
receptor family contains one individual binding site (9, 10).
The three-subunit composition of P2X receptors was sup-
ported in addition to the already mentioned biochemical evi-
dence (2) by a wealth of further data. (a) Single channel analy-
sis of P2X receptor currents indicated 2–3 sequential binding
steps (11, 12). (b) The kinetic behavior of P2X receptor cur-
rents was simulated with an allosteric model describing chan-
nel opening in the di- or triliganded state (13, 14). (c) Atomic
force microscopy provided evidence for three receptor sub-
units, which moved away from the central pore as the channel
opened (15, 16). (d) Fluorescence resonance energy transfer
and electron microscopy supplied a rough structure of three
interacting subunits (17). (e) The crystal structure of a ze-
brafish (zf) P2X4 receptor mutant supported the existence of
corresponding intersubunit pockets as the binding site for
ATP (17, 18).
Because in P2X receptors, instead of a few amino acid resi-
dues, four clusters of AAs, termed nucleotide binding do-
mains (NBD1–4 (19); here nucleotide binding segments;
NBS1–4), were identified as possible docking places for ATP
(see Fig. 1A), we investigated by Ala scanning mutagenesis the
functional significance of these NBSs. For this purpose, the
human (h) recombinant P2X3 receptor, located at sensory
neurons and participating in pain sensation (20, 21), was ex-
pressed in HEK293 cells or Xenopus laevis oocytes, and the
P2X1,3 receptor-selective ,-methylene ATP (,-meATP)
was used as an agonist (22). In contrast to ,-meATP, ATP
itself would have the drawback of also activating P2Y recep-
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tors negatively interacting with the stimulatory effect at P2X3
(23).
P2X1 and P2X3 receptors show, in contrast to all other P2X
receptor subtypes, a rapidly desensitizing behavior; this may
be due to differences in either the AA composition/length of
the N or C terminus (24–27) or the AA composition/length
of the second transmembrane domain (27). Moreover, the
phosphorylation of consensus protein kinase C sites at the
extracellular loop of the P2X3 receptor might also modify
the agonist-induced desensitization (28, 29). Eventually, rapid
desensitization may also depend on agonist binding to a non-
conserved AA at the extracellular loop, which is absent in the
slowly desensitizing receptor types. Thus, patch clamp and
two-electrode voltage clamp measurements, as well as the
Ca2 imaging technique, were used to investigate the role of
all conserved and some non-conserved AA residues arranged
in NBSs and located at the interface of two subunits for deter-
mining the amplitude and time course of the agonist-induced
responses.
EXPERIMENTAL PROCEDURES
Culturing of HEK293-hP2X3 Cells—HEK293 cells were
kept in Dulbecco’s modified Eagle’s medium also containing
4.5 mg/ml D-glucose (Invitrogen), 2 mM L-glutamine (Sigma-
Aldrich), 10% fetal bovine serum (Invitrogen) at 37 °C and
10% CO2 in humidified air.
Site-directedMutagenesis and Transfection Procedures—
The human P2X3 receptor (hP2X3) cDNA (GenBankTM ac-
cession number NM-002559.2) was subcloned per PstI and
EcoRI restriction sites into pIRES2-EGFP vector from Clon-
tech Laboratories for independent expression of P2X3 and
EGFP, creating the pIR-P2 plasmid. All P2X3 receptor mu-
tants were generated by introducing replacement mutations
into the pIR-P2 construct using the QuikChange site-directed
mutagenesis protocol from Stratagene according to the in-
struction manual. HEK293 cells were plated in plastic dishes
(electrophysiology) or onto coverslips (Ca2 imaging) 1 day
before transient transfection. 0.5 g of plasmid DNA per dish
was combined with 10 l of PolyFect reagent from Qiagen
and 100 l of Opti-MEM (Invitrogen). After 10 min of incu-
bation, the lipid-DNA complexes were introduced to the cells.
Approximately 18 h after transfection, the medium was re-
placed with Opti-MEM to remove residual plasmid DNA.
Whole-cell Patch Clamp Recordings—Whole-cell patch
clamp recordings were performed 2–3 days after the transient
transfection of HEK293 cells, at room temperature (20–
22 °C), using an Axopatch 200 B patch clamp amplifier (Mo-
lecular Devices). The pipette solution contained (in mM): 140
CsCl, 1 CaCl2, 2 MgCl2, 10 HEPES, and 11 EGTA, pH ad-
justed to 7.4 using CsOH. The external physiological solution
contained (in mM): 135 NaCl, 4.5 KCl, 2 CaCl2, 2 MgCl2, 10
HEPES, and 10 glucose, pH adjusted to 7.4 using NaOH. The
pipette resistances were 3–6 megaohms. The liquid junction
potential (VLJ) between the bath and pipette solution at 21 °C
was calculated and was found to be 4.5 mV. Holding potential
values given in this study were corrected for VLJ. All record-
ings were made at a holding potential of65 mV. Data were
filtered at 2 kHz with the inbuilt filter of the amplifier, digi-
tized at 5 kHz, and stored on a laboratory computer using a
Digidata 1440 interface and pClamp 10.2 software (Molecular
Devices).
Drugs were dissolved in the external solution and locally
superfused to single cells (detected by their EGFP fluores-
cence), using a rapid solution change system (SF-77B Perfu-
sion Fast-Step, Warner Instruments; 10–90% rise time of the
junction potential at an open pipette tip was 1–4 ms; but see
below). Concentration-response curves were established by
applying increasing concentrations of ,-methylene ATP
(,-meATP; Sigma-Aldrich) for 2 s. The intervals between
applications were 5 min for 0.03–1 M and 7 min for 3–300
M. Under these conditions, agonist responses were repro-
ducible at the given concentrations (30).
In experiments investigating the kinetics of P2X3 currents,
,-meATP (100 M) was applied for 10 s with 7-min inter-
vals three times in total. The current induced by the second
application was used for calculations. The decay phases of the
curves were fitted by the following biexponential equation
y  A1  e
t/des1 A2 e
t/des2 P (Eq. 1)
using the in-built function of the pClamp 10.2 software (Mo-
lecular Devices), where A1 and A2 are the relative amplitudes
of the first and second exponential, des1 and des2 are the de-
sensitization time constants, and P is the plateau. The onset
time constants (on(10–90%)) were calculated from the individ-
ual recordings under the assumption that despite the rela-
tively slow local application, they give a rough approximation
of the kinetics of channel opening.
Macroscopic Conductance Kinetics—Macroscopic conduc-
tance kinetics were analyzed by a hidden Markow model (see
supplemental Fig. 2A, panel a; derived from Ref. 14) that in-
cludes binding, gating, and desensitization. Kinetic modeling
and fitting were performed by the QuB software (31). To esti-
mate solution exchange times of the rapid superfusion system
used, 150 mM KCl was applied to the cell. The time constant
of this test pulse (140 ms) was determined by a single expo-
nential fit and used for modeling the wash in and wash out of
,-meATP.
High ,-meATP concentrations induce large and rapidly
activating currents, leading to a reduced membrane potential.
Hence, for kinetic fits, the whole-cell conductance  was cal-
culated from the measured current I, the access resistance Ra,
the membrane resistance Rm, and the holding potential Uh,
using the following equation.
 
Ra  Rm
2
Ra
2Rm RaRm
2 
Rm
2Uh
I
(Eq. 2)
Ca2Microfluorometry—HEK293 cells were loaded 2–3
days after transient transfection with the Ca2-sensitive fluo-
rescent dye Fura-2 acetoxymethyl ester (2.5 M; Sigma-
Aldrich) at 37 °C for 30 min in culture medium. To remove
extracellular traces of the dye, the cells were then washed in
physiological solution of the same composition as that used
for patch clamp measurements. Cells plated onto coverslips
were mounted into a perfusion chamber and placed on the
P2X3 Receptor Agonist Binding Site
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stage of an inverted microscope (IX-70; Olympus) with epif-
luorescence optics and a cooled CCD camera (IMAGO; Till
Photonics). Throughout the experiments, cells were continu-
ously superfused at 0.8 ml/min by means of a roller pump
with external solution. Intracellular Fura-2 was alternately
excited at 340 and 380 nm, and the emitted light was mea-
sured at a wavelength of 510 nm. The TILL vision software
(3.3 Till Photonics) was used for data acquisition, system con-
trol, and later, off-line analysis. The fluorescence ratio (FR;
340/380 nm) provides a relative measure of the cytosolic free
Ca2 concentration ([Ca2]i).
For the determination of concentration-response relation-
ships, ,-meATP was pressure-injected locally, by means of
a computer-controlled DAD12 superfusion system (ALA Sci-
entific Instruments, Inc.). The application time was 5 s, and
the intervals between two subsequent agonist applications
were kept, independent of the concentration used, at 15 min.
Expression of P2X3 Receptors and Their Mutants in X. laevis
Oocytes—An oocyte expression plasmid harboring the cDNA
for an N-terminally hexahistidine-tagged (His-tagged) hP2X3
subunit was available from a previous study. Replacement
mutations were introduced by QuikChange site directed-mu-
tagenesis (Stratagene). All constructs were verified by restric-
tion analysis and nucleotide sequencing. Capped cRNAs were
synthesized and injected into collagenase-defolliculated
X. laevis oocytes using a Nanoliter 2000 injector (World Pre-
cision Instruments) as described previously (2, 32). Oocytes
were cultured at 19 °C in sterile oocyte Ringer’s solution (ORi:
90 mM NaCl, 1 mM KCl, 1 mM CaCl2, 1 mM MgCl2, and 10 mM
Hepes, pH 7.4) supplemented with 50 g/ml gentamycin.
Two-electrode Voltage Clamp Electrophysiology—2–3 days
after cRNA injection, current responses were evoked by ,-
meATP as indicated, at ambient temperature (21–24 °C), and
recorded by conventional two-electrode voltage clamp with a
Turbo TEC-05 amplifier (npi Electronics) at a holding poten-
tial of60 mV as described previously (33). Oocytes were
continuously perfused by gravity (5–10 ml/min) in a small
flow-through chamber with a nominally calcium-free ORi
solution (designated Mg-ORi), in which CaCl2 was replaced
by equimolar MgCl2 to avoid a possible contribution of en-
dogenous Ca2-dependent Cl channels to the ,-meATP
response.
Dilutions of agonists and antagonists in Mg-ORi were pre-
pared daily and applied by bath perfusion. Switching between
bath solutions was controlled by a set of magnetic valves, ena-
bling computer-controlled applications of compounds (Cell-
Work Lite 5.1 software; npi Electronics). For concentration-
response analysis, rapidly desensitizing hP2X3 receptors were
first repetitively activated in 1-min intervals by 10-s applica-
tions of 100 M ,-meATP (which is maximally effective at
the wild-type (WT) hP2X3 receptor) until constant current
responses were obtained (for further experimental details, see
Ref. 33).
Protein Labeling, Purification, and PAGE—cRNA-injected
oocytes were metabolically labeled by overnight incubation
with L-[35S]methionine and, just before protein extraction,
additionally surface-labeled with Cy5 NHS ester, an amine-
reactive, membrane-impermeant fluorescent dye (34). His-
tagged proteins were purified by nickel-nitrilotriacetic acid
agarose (Qiagen) chromatography from digitonin (1%, w/v)
extracts of oocytes and analyzed by blue native PAGE as de-
scribed previously (2, 3). Where indicated, samples were
treated before blue native PAGE for 1 h at 37 °C with 0.1%
(w/v) SDS or a combination of 0.1% (w/v) SDS and 100 mM
DTT, to induce partial dissociation of hP2X3 complexes.
For SDS-urea-PAGE, proteins were denatured by incuba-
tion with reducing SDS sample buffer for 15 min at 56 °C and
electrophoresed in parallel with 14C-labeled molecular mass
markers (Rainbow, Amersham Biosciences) on SDS-urea-
PAGE gels (10% acrylamide). SDS-urea-PAGE gels were
scanned wet with a fluorescence scanner (Typhoon, GE
Healthcare) for visualization of fluorescently labeled plasma
membrane-bound proteins and then dried and exposed to a
phosphor screen for subsequent PhosphorImager (Storm 820,
GE Healthcare) detection of 35S incorporation. The figures
were prepared by using ImageQuant TL v2005 (Amersham
Biosciences) for contrast adjustments and Adobe Photoshop
CS 8.0 for level adjustment and cropping.
Homology Modeling—We modeled, based on the published
crystal structure of the zfP2X4 channel in its closed state (18),
the extracellular loop and transmembrane areas of the hP2X3
receptor. The software used was Modeler 9, version 7 (35).
The alignment was determined by the align2D function,
which also takes the secondary structure of the template into
consideration. Homology modeling was made with the loop-
model function with high optimization settings. Visualization
of the results was by VMD (36).
Data Analysis—Concentration-response curves for ,-
meATP were fitted by using a three-parametric Hill plot
(SigmaPlot; SPSS). The figures show mean S.E. values of n
experiments. One-way analysis of variance followed by Holm-
Sidak post hoc test was used for statistical analysis. We com-
pared the various current and [Ca2]i parameters (amplitude
and/or time course) of the mutants within NBS1–4 with the
WT data. A probability level of 0.05 or less was considered to
reflect a statistically significant difference.
RESULTS
Agonist Sensitivity of hP2X3 ReceptorMutants
Patch Clamp Investigations—The underlined, conserved
AA residues in NBS1–4 of hP2X3 were sequentially replaced
by Ala, one or two at a time (Fig. 1A). In addition, the con-
served Ala-283 was substituted by Asp or Arg. We have also
chosen non-conserved AA residues in each NBS and replaced
them by Ala (Fig. 1A). The functional significance of AAs was
checked by using the P2X1,3-selective ,-meATP as an
agonist.
The hP2X3 receptor or its mutants were transiently ex-
pressed either in HEK293 cells or in X. laevis oocytes. Fig. 1B
documents the agonist application protocols in WT HEK293-
hP2X3 cells. When recorded by the whole-cell variant of the
patch clamp technique, at a holding potential of65 mV,
,-meATP had already caused a prominent desensitization
of the inward current during its 2-s superfusion period (Fig.
1B, panel a). We kept a 5–7-min interval between the applica-
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tion of successively increasing ,-meATP concentrations to
allow recovery of agonist sensitivity. ,-meATP caused a
concentration-dependent increase of the intracellular [Ca2]i
transients in HEK293-hP2X3 cells as well, with a slow decline
to the pre-drug level. In these experiments, we superfused
,-meATP for 5 s and correspondingly prolonged the appli-
cation intervals from 5–7 to 15 min (Fig. 1B, panel b). It is
noteworthy that extracellular Ca2 appeared to enter the cells
via the P2X3 receptor channels only because a Ca2-free bath
medium almost abolished the effect of ,-meATP (37). Fi-
nally, the ,-meATP-induced inward currents and [Ca2]i
transients were strongly depressed by the P2X1–3 antagonist
TNP-ATP or the P2X3-selective antagonist A317491 (37).
In the following experiments, we singly or doubly replaced
all conserved AA residues within NBS1–4 of the hP2X3 sub-
unit by Ala (Fig. 2); the only exception was the neutral Ala-
283 itself, which was substituted by the negatively charged
Asp or the positively charged Arg. Then, we transfected both
the WT receptor and its NBS mutants into HEK293 cells and
compared the current responses measured by the patch clamp
technique. The concentration-response curve for ,-meATP
at the WT receptor yielded an EC50 of 2.66 0.67 M, an Imax
of 4,110 310 pA, and a Hill coefficient of 1.47 0.47 (n
8–12). It is noteworthy that the EC50 values correlated well
with those reported previously, both by ourselves (30) and by
other authors (38).
When concentration-response curves were determined for
,-meATP at the mutant receptors, it became evident that
several AA substitutions interfered with the agonist effect.
First of all, replacement of Ala-283 by Asn or Arg caused a
decrease in the activity of ,-meATP. It was not possible to
determine EC50 or Imax values at the A283D and A283R mu-
tants because no clear maximum of the concentration-re-
sponse curve was reached up to 300 M. The current ampli-
tudes at this ,-meATP concentration were 380.7 95.9 pA
(A283D; n 6) and 2,996 1,553 pA (A283R; n 5), respec-
tively; a statistically significant inhibition was observed only
when the Imax value at the WT receptor (4,110 310 pA; see
above) was compared with effect of ,-meATP (300 M) at
the A283D mutant. Thus, AAs carrying a negative or positive
charge at position 283 perturbed the ability of the receptor
channel to open.
In NBS1, the amino acid residues Lys-63 and Gly-66, in
NBS2, the residues Thr-172, Lys-176, and Asn-177, in NBS3,
the residues Asn-279, Arg-281, and Lys-284, and eventually in
NBS4, the residues Lys-299 and Arg-295 were essential for
the agonist response. Although of less importance, modifica-
tions at Lys-65 (NBS1), Phe-174 (NBS2), Phe-280 and Phe-
282 (NBS3), and Gly-302 (NBS4) also caused moderate
changes. Replacements of Thr-62 (NBS1), Phe-171 (NBS2),
and Leu-297 or F301A (NBS4) by Ala had no effect. There
was no obligatory relationship between an AA being con-
FIGURE 1. Current responses to ,-meATP of theWT hP2X3 receptor and its NBSmutants in HEK293 cells. A, AA residues of the supposed nucleotide
binding segments (NBS1–4). Bold characters, conserved AAs; underlined characters, substitution by Ala. B, panel a, whole-cell current responses, induced by
,-meATP (0.03–30 M), were recorded with the patch clamp technique at a holding potential of65 mV. Increasing concentrations of the agonist were
locally superfused for 2 s with 5- or 7-min intervals as indicated. Panel b, increases in the intracellular calcium concentration ([Ca2]i) were induced by ,-
meATP (0.3–300 M). Increasing concentrations of the agonist were locally superfused for 5 s with 15-min intervals. The cells were labeled with the calcium-
sensitive fluorescent dye Fura-2, and fluorescence ratio (FR340/380) measurements were made with a dual wavelength spectrometer (alternating excitation
at 340 and 380 nm). The changes in FR were used as a measure of [Ca2]i. Representative tracings are shown in both panels a and b. C, panel a, ,-meATP
(30 M)-induced charge transfer measured by the patch clamp technique and fluorescence ratio determined by Ca2 imaging as a function of time. The
time courses of these responses were similar. Two representative experiments are shown out of a total of three (current response) and four ([Ca2]i tran-
sients) similar ones (2-s application time). pC, picocoulombs. Panel b, the current response to ,-meATP (30 M) and the differentiated F340/380/dt also have
similar time courses. The recordings from panel awere replotted in panel b.
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served or non-conserved and the magnitude of inhibition.
Some conserved (e.g. Lys-63) and non-conserved (e.g. Lys-
284) AAs were both of great importance for the agonist effect,
whereas other non-conserved (e.g. Thr-62) and conserved (e.g.
Phe-171) AAs were of minor significance. It turned out to be
especially interesting that although some single mutations of
adjacent, conserved AAs in NBS1, -2, and -3 failed to abolish
the current response, the respective double mutations (K65A/
G66A, F171A/T172A, N279A/F280A, F280A/R281A) caused
complete inhibition (supplemental Fig. 1). However, the dou-
ble mutation of two non-adjacent, conserved AAs (F171A/
N177A) within NBS2 did not decrease the ,-meATP re-
sponse further when compared with F171A alone.
Ca2 Imaging Studies—The evaluation of the ,-meATP
concentration-response curves for [Ca2]i transients in
HEK293 cells transfected with the WT hP2X3 receptor
yielded an EC50 value of 1.86 0.21 M, an 	FRmax of 0.45
0.01, and a Hill coefficient of 3.16 0.64 (n 14–19) (Fig. 3).
The agonist effects were modified by mutations of individual
AAs within NBS1–4 to Ala. Moreover, the replacement of
Ala-283 by Asp or Arg decreased the ,-meATP-induced
increase of [Ca2]i. It was not possible to determine EC50 or
Imax values at the A283D and A283R mutants because no
clear maximum of the concentration-response curve was
reached up to 300 M. The [Ca2]i transients at this ago-
nist concentration were 0.15  0.01 (A283D; n  32) and
0.35  0.04 (A283R; n  35), respectively; a statistically
significant inhibition was observed when the 	FRmax value
at the WT receptor (0.45  0.01; see above) was compared
with the effect of ,-meATP (300 M) at both mutants.
Thus, AAs carrying a negative or positive charge at posi-
tion 283 perturbed the ability of the receptor to interact
with its agonist.
All these changes were basically similar to the situation
when current responses were used as a measure of agonist
potency. However, in contrast to patch clamp measure-
ments, where T62A, F172A, L297A, and F301A did not
considerably modify the ,-meATP sensitivity, Ca2 im-
aging also demonstrated small changes with these mutants.
It should be kept in mind that because of the possibility to
measure [Ca2]i simultaneously in many cells, the number
of experiments was in this case higher than with patch
FIGURE 2. Current responses to ,-meATP in HEK293 cells transfected with theWT hP2X3 receptor and its mutants.Whole-cell patch clamp record-
ings were made as described in the legend for Fig. 1. Concentration-response curves for ,-meATP were constructed both for the WT hP2X3 receptor and
for its point mutants, where the indicated AAs in their nucleotide binding segments were replaced by Ala (in Fig. 1A, see underlined one-letter coding of
AAs). Ala was sequentially introduced to substitute individual AAs in NBS1 (a), NBS2 (b), NBS3 (c), and NBS4 (d). Each symbol indicates the mean S.E. of
5–13 cells.
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clamp recordings, where each cell had to be patched sepa-
rately. We assume that the combination of these two meth-
ods allows a more reliable observation of subtle changes
than the measurement of current responses or [Ca2]i
transients alone (39, 40).
It is certainly true that electrophysiology directly deter-
mines the cationic fluxes through the P2X3 receptor channel,
whereas [Ca2]i transients are only a consequence of the en-
try of Ca2 via this receptor channel into the intracellular
space. However, the two methods equally well describe the
same phenomenon. In representative experiments, we inte-
grated the ,-meATP (30 M) currents through the WT
P2X3 receptor to obtain the total amount of transferred
charge (n 3) and found its time course similar to that of the
[Ca2]i transients (measured as fluorescence ratio; 	FR) (n
4; Fig. 1C, panel a). Then, the shape of the current response to
,-meATP was compared with that of the differentiated
[Ca2]i response and was found to perfectly correlate (Fig. 1C,
panel b) (41); rapid desensitization was a characteristic fea-
ture of the receptor when either method was used for
recording.
Comparison of Data Obtained by Patch ClampMeasurements
and Ca2 Imaging Studies
Fig. 4 summarizes the data obtained by electrophysiology
and Ca2 imaging. The EC50 and the maximal effect Emax
(Imax and 	FRmax, respectively) values calculated from the
concentration-response curves are shown both for the WT
receptor and for its Ala-substituted single or double mutants.
As already mentioned above, qualitatively identical results
were obtained by the two techniques, although quantitative
differences exist. With some of the mutants, no clear maxi-
mum of the concentration-response curve (and as a conse-
quence EC50 or Emax values) could be determined with one or
both of these techniques. With these limitations in mind,
there was no response to ,-meATP at the K63A, K176A,
R295A, and K299A mutants, in agreement with the sugges-
tion that certain positively charged AAs are associated with
FIGURE 3. Increases of intracellular calcium by ,-meATP in HEK293 cells transfected with theWT hP2X3 receptor and its mutants. FR measure-
ments were made as described in the legend for Fig. 1 and were taken as a measure of [Ca2]i. Concentration-response curves for ,-meATP were con-
structed both for the WT hP2X3 receptor and for its point mutants, where the indicated AAs in their nucleotide binding segments were replaced by Ala (in
Fig. 1A, see underlined one-letter coding of AAs). Ala was sequentially introduced to substitute individual AAs in NBS1 (a), NBS2 (b), NBS3 (c), and NBS4 (d).
Each symbol indicates the mean S.E. of 9–20 cells.
P2X3 Receptor Agonist Binding Site
2744 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 286•NUMBER 4•JANUARY 28, 2011
 at ZEN
TR
ALBIBLIO
THEK M
EDIZIN, on M
arch 4, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
the binding of the negatively charged phosphate groups of
ATP (5–7). The changes in EC50 and Emax with the addi-
tional mutants, as well as the experiments with mutating
Ala-283 to Asp or Arg, confirmed our assumption that all
conserved AAs in the NBSs play some role in agonist bind-
ing, the stabilization of the secondary protein structure, or
the transduction of receptor binding to channel gating. A
comparable function of at least some of the non-conserved
AAs was also evident.
Activation, Gating, and Desensitization of hP2X3 Receptor
Mutants
A further question to be answered was whether some of the
mutations altered the shape of the current response by inter-
fering with channel activation or desensitization. Fig. 5a
shows original tracings of ,-meATP (100 M) responses on
mutants, where the current amplitude, its activation time, or
the rate of desensitization appeared to change in comparison
with the WT receptor. It is noteworthy that a slower rate of
desensitization (higher des1, des2 values; see below) may also
be caused by a slower gating of the P2X3 receptor channel. In
these experiments, ,-meATP was applied for only 2 s; the
rate constants were calculated from similar experiments with
10-s application times (not shown; see “Experimental Proce-
dures”). According to expectations, WT P2X3 exhibited a
rapid activation time constant (on, 38 4 ms) and an ex-
tremely rapid fading of the current amplitude with the two
desensitization time constants des1 (935 128 ms) and des2
(133 12 ms; n 8 each). The T62A, F171A, and L297A
mutants exhibited current amplitudes similar to those of the
WT receptor (Figs. 2 and 4); neither their on nor their des1/
des2 values differed in a statistically significant manner from
the WT controls. The mutation of Lys-65 to Ala did not
FIGURE 4. Summary of ,-meATP concentration-response curves for
the hP2X3 receptor and its NBS mutants in HEK293 cells. Curves pre-
sented in Figs. 2 and 3, and supplemental Fig. 1 were fitted as described
under “Experimental Procedures” to obtain the EC50 and Emax (Imax or
	FRmax) values. On the left-side graph, the EC50 values of the indicated
mutants are expressed in M. On the right-side graph, the Emax values of
the same mutants are expressed in pA and 	FR, respectively. Current (a)
and FR (b) measurements are indicated for each single and double mu-
tant. Each symbol indicates mean  S.E. of 4–13 (a) and 9–20 (b) cells.
With several mutants, no clear maximum of the concentration-response
curve was reached, and therefore neither the EC50 nor the Emax values
could be reliably determined. In such cases, the EC50 values were not
indicated, and the Emax values were replaced with the effect of the high-
est agonist concentration tested (300 M; designated by a thick line). *,
p 
 0.05; statistically significant difference from the respective value
measured with the WT receptor.
FIGURE 5.Original recordings of ,-meATP-induced currents at hP2X3
receptors or its NBSmutants. The expression systems of the HEK293 cell
(a, left panel; experimental conditions were as described in the legend for
Fig. 1) or the Xenopus leavis oocyte (b, right panel; holding potential,60
mV; agonist application was for 10 s every 1 min) were used. a, ,-meATP
(100 M) effects are shown at those mutants only, where either the ampli-
tude or the time course of the current responses appeared to be modified
in comparison with the WT receptor. b, ,-meATP (100 M) effects are
shown at nine selected mutants only, where the amplitude and/or the time
course of current responses appeared to be modified in comparison with
the WT receptor. These mutants were tested for assembly and surface ex-
pression in the oocyte system in the following experiments (Fig. 6B). Repre-
sentative recordings for 5–14 experiments are shown.
P2X3 Receptor Agonist Binding Site
JANUARY 28, 2011•VOLUME 286•NUMBER 4 JOURNAL OF BIOLOGICAL CHEMISTRY 2745
 at ZEN
TR
ALBIBLIO
THEK M
EDIZIN, on M
arch 4, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
change the current amplitude but prolonged the onset time
constant on (270 50 ms; p
 0.05) and increased both de-
sensitization time constants (des1, 4,121 945 ms; des2,
690 95 ms; n 7; p
 0.05). The G66A mutant exhibited
smaller current responses than the WT receptor, with a re-
duction of the rise and decay times (on, 310 45 ms; des1,
5,477 1,480 ms; des2, 740 105 ms; n 10; p
 0.05). The
current responses at the T172A and N177A mutants were
also smaller than those at the WT receptor, although the rate
of desensitization was unaltered. Eventually, smaller ampli-
tudes were accompanied either by decelerated (N279A, on,
487 60 ms; des1, 21,830 7,060 ms; des2, 2,168 501 ms;
n 9; p
 0.05) or by practically non-existent desensitization
(R281A), at least during the 2–10-s application times of the
present experiments. In the case of K284A, the on values in-
creased (151 18 ms; p
 0.05), whereas the des1 (2,376
133 ms) and des2 values (418 30 ms; n 10 and p 0.05
each) did not alter.
For the WT P2X3 receptor and a number of its mutants, we
constructed kinetic fits of the ,-meATP-induced currents
by using a hidden Markow model obtained by simplification
of the model of Karoly et al. (14). The rate constants charac-
terizing transitions between the unbound, closed-state recep-
tor (C1), and the receptor binding one- (C2), two (C3)-, or
three (C4)-agonist molecules, as well as the two open-state
receptors (O5, O6) and the two desensitized receptors (C7, C8)
are shown for WT P2X3 on the supplemental Fig. 2A, panel a.
By using the on- and off-rate constants, the shape and ampli-
tude of the ,-meATP (0.3–300 M)-induced currents could
be computer-modeled; the quality of the fits can be judged by
the close parallelism of the black lines (original tracings) and
the current traces (orange lines) calculated with the indicated
rate constants for binding (C1-C4), gating (C3-O5; C4-O6), and
desensitization (C3-C7 and O5-C7; C4-C8 and O6-C8). Best fits
for the ,-meATP currents were computed by modifying the
rate constants as indicated in the individual panels of supple-
mental Fig. 2. By comparing these constants with those of the
WT receptor, it appears that in the case of K65A (B) and
F280A (D), binding was altered, whereas in the case of F174A
(C), both binding and gating were altered. Thus, selected mu-
tations within NBS1–3 are suggested to modify agonist bind-
ing to a variable degree, although in some cases, gating may
also be affected. The quality of the best fit for R281A (E) was
moderate, indicating on the one hand changes in binding, but
on the other hand raising the possibility of additional compli-
cating factors such as the interruption of hydrogen bounds
formed between Arg-281 and Glu-156 on the same subunit
and/or Asp-76 on the neighboring subunit (see “Homology
Modeling of the hP2X3 Receptor” below). Similarly, the modi-
fication of the rate constants failed to produce a good fit for
agonist currents at Lys-284 (not shown). This may be due to
the fact that Lys-284 is situated at the entry of the ion pore
region and is not directed toward the binding groove. We
simplified the model of Karoly et al. (14) by omitting the ki-
netic constants determining high affinity desensitization and
the recovery from desensitization but maintained those in-
volved in the early phase of desensitization. Of course, this
simplification means a loss of quality, but the obtained fits
should be sufficient to decide whether binding and/or gating
are responsible for the modified amplitudes and time courses
of the current responses.
Assembly and PlasmaMembrane Trafficking of hP2X3
ReceptorMutants
To check for expression system-specific differences and
also to assess their assembly capacitance, we expressed se-
lected mutants (K63A, G66A, T172A, K176A, N279A, R281A,
K284A, R295A, and K299A), which responded in HEK cells
with rather small or even no current amplitudes to ,-
meATP (100 M) in X. laevis oocytes. The ,-meATP con-
centration-response curve of oocyte-expressed WT hP2X3
receptors exhibited EC50 and Emax values of 3.14 0.75 M
and 3.68 0.41 A, respectively; the Hill coefficient was
1.28 0.49 (n 6 each). In agreement with the patch clamp
data in HEK293 cells, the ,-meATP (100 M)-induced cur-
rent responses were markedly depressed or even abolished on
the selected mutants in comparison with WT hP2X3 receptor
currents (Fig. 6A). In addition, changes in the speed of activa-
tion and desensitization were also comparable in recordings
from oocytes and HEK293 cells (compare Fig. 5b with 5a). It
should be noted, however, that because of the relatively slow
application speed and the short inter-application interval of
,-meATP (100 M) (see “Experimental Procedures”), no
time constants for activation/desensitization were calculated
for oocytes.
The mutations may affect the assembly and cell surface
expression of the hP2X3 mutants. To address this issue, we
used the nine single mutants with impaired function in
the oocyte expression system, which has the strong advantage
that the cell integrity needed for reliable cell surface labeling
can be easily assessed by visual inspection. Assembly (Fig. 6B,
panel a) and cell surface expression (Fig. 6B, panel b) were
investigated by blue native PAGE in the [35S]methionine-la-
beled form and by SDS-PAGE in the Cy5 cell surface-labeled
form, respectively. Like the WT hP2X3 receptor subunit, all
P2X3 mutants with impaired function were also capable of
assembling to homotrimers (Fig. 6B, panel b). All mutants
appeared at the cell surface, albeit at different levels (note for
example the rather weak surface expression of R295A and
K299A). Thus, with these two mutants, the failure of ,-
meATP (100 M) to induce a current response (Fig. 6A) may
be due at least partly to the low degree of plasma membrane
expression. However, in the case of all other mutants investi-
gated in the oocyte system, the trafficking to the cell mem-
brane was roughly equal with that of the WT receptor.
HomologyModeling of the hP2X3 Receptor
Eventually, based on the published crystal structure of the
zfP2X4 (18), we modeled the hP2X3 receptor. The NBSs
shown to be involved in agonist binding were situated at op-
posite sites of the same subunit (Fig. 7B) and were therefore
able to form a binding pocket only at the interface of two ad-
jacent subunits (Fig. 7A, panels a and b). Of the conserved
residues investigated, many were oriented toward the groove
of the pocket, indicating that they may bind ATP directly
(Lys-63, Lys-65, Lys-176, Asn-279, Arg-281, Arg-295, Lys-
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299); our experiments confirm that Ala substitution of these
AA residues causes marked changes in the amplitude and/or
gating and possibly desensitization kinetics of the current re-
sponses. In contrast, some of the conserved AA residues, such
as Thr-172, Asn-177, and Phe-280, were oriented away from
the groove, although their replacement with Ala caused pro-
nounced changes, suggesting that they may participate in
transducting conformational information changes from the
binding pocket to the ion channel. Ala-283 is located rela-
tively far from the binding pocket; however, the substitution
of Ala by negatively (Asn) or positively (Arg) charged AAs had
prominent effects. Ala substitution of the non-conserved AAs
Thr-62, Phe-174, Phe-282, and Phe-301 caused only minor
changes, irrespective of their orientation toward (Phe-174,
Phe-301) or away (Thr-62, Phe-282) from the binding pocket.
Replacement of the non-conserved Lys-284 by Ala had a
marked effect both on the current amplitude and on its time
course. However, structural considerations in conjunction
with our poor kinetic fits make the involvement of this AA in
agonist binding unlikely (see “Activation, Gating, and Desen-
sitization of hP2X3 Receptor Mutants”).
DISCUSSION
P2X3 receptors are mostly limited to the neuronal path-
ways involved in the perception and conduction of painful
stimuli (20, 21). This highly circumscribed distribution in the
peripheral and central nervous system is a prerequisite to de-
velop new drugs for the selective treatment of pain. The pe-
ripheral terminals of sensory neurons, situated for example in
dorsal root ganglia, possess P2X3 receptors, which react to
ATP released by all types of nociceptive stimuli. Antagonists
at these receptors have been shown to effectively block both
hyperalgesia and allodynia in different models of pathological
pain (42).
In view of the great significance of P2X3 receptors for fu-
ture therapeutic strategies to medicate various pain states, we
set out to investigate the AA residues involved in agonist
binding, the more so because in contrast to most P2X recep-
tor types, in the case of P2X3, we dispose of some selective
agonists and antagonists (22). Our purpose was to character-
ize the ATP binding site of the P2X3 receptor to alleviate the
computer-assisted design of new antagonists for therapeutic
purposes. Although mutagenesis studies at P2X1 (6, 8, 43, 44),
P2X2 (7, 45), and P2X4 (39, 40) have identified several AA
residues of the respective receptors, which are indispensable
for agonist binding, similar information for P2X3 receptors is
scarce (45) (Table 1). Bioinformatics and receptor modeling
suggested the existence of four putative ATP binding sites per
each subunit (19, 46). The possibility of there being more than
one ATP binding site per monomer cannot be ruled out at the
present (17) but is rather unlikely. More importantly, instead
of individual amino acids, groups of AAs organized in four
nucleotide binding segments were proposed to mediate the
nucleotide effects (19).
In the present study, we systematically replaced all con-
served AAs in the NBSs of the hP2X3 subunit (plus 1–2 non-
conserved AAs in each NBS) and searched for changes in ago-
nist potency by means of electrophysiology and Ca2 imaging
in two expression systems (HEK293 cells, X. laevis oocytes).
In the first place, we confirmed our previous results relating
to the critical importance of a few positively charged AAs
(K63A, K65A, K176A, R281A, R295A, K299A (37, 45)). Then,
the involvement of a range of further AAs in agonist binding,
agreeing with a comparable role of these AAs in the hP2X1,
rP2X2, and rP2X4, was also documented (Table 1 and refer-
ences cited therein). However, we report in addition three key
findings. 1) Unequivocal, although sometimes minor, changes
FIGURE 6. Sensitivity to ,-meATP and assembly and surface expres-
sion of hP2X3mutants in X. laevis oocytes. A, typical two-electrode volt-
age clamp current traces recorded from oocytes expressing the hP2X3 re-
ceptor or its selected NBS mutants as indicated. ,-meATP (100 M)
caused smaller current amplitudes at all nine mutants tested than at the WT
receptor. Mutants K63A, K276A, and K299A were unable to mediate any
current response. Each symbol indicates mean S.E. of 5–6 oocytes. *, p

0.05; statistically significant difference from the WT receptor. B, [35S]methi-
onine-labeled oocytes were chased for 24 h and surface-labeled with the
membrane-impermeant fluorescent Cy5 dye prior to protein purification by
non-denaturing nickel-nitrilotriacetic acid chromatography. B, panel a, olig-
omeric state of the P2X3 proteins as visualized by blue native PAGE and
35S phosphorimaging. The ovals schematically illustrate the migration posi-
tions of the non-denatured trimeric state and dimeric and monomeric
states produced by partial or complete denaturation with SDS treatment,
respectively. Panel b, aliquots of the same samples shown in panel awere
denatured with reducing SDS-PAGE sample buffer, resolved by SDS-urea-
PAGE, and visualized in their Cy5-labeled surface form by Typhoon fluores-
cence scanning. Each mutant was analyzed at least twice with identical
results.
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occurred in the amplitude of the current and/or [Ca2]i re-
sponse when further conserved (Phe-171, Leu-297) or non-
conserved (Thr-62, Phe-174, Lys-284, Phe-301) AAs were
replaced by Ala or Ala itself was substituted by other AAs
(A283D, A283R). 2) The agonist potency decrease was addi-
tive when two adjacent AAs were replaced simultaneously by
Ala (Lys-65/Gly-66, Phe-171/Thr-172, Asn-279/Phe-280,
Phe-280/Arg-281) but was not altered after Ala substitution
of two non-adjacent AAs of the same NBS (Phe-171/Asn-
177). 3) The decrease in current amplitude was accompanied
in many cases by a pronounced decrease in the activation
and/or desensitization rate of the receptor mutants (K65A,
G66A, N279A). With R281A, a depression of the current am-
plitude was not accompanied by a concomitant change in the
speed of activation or desensitization.
Signals that regulate intracellular trafficking of P2X recep-
tors and thereby their membrane expression are usually asso-
ciated with the N (47) or C terminus of these receptors (48,
49). Disrupting some of the conserved disulfide bridges of the
extracellular loop of P2X subunits also markedly depresses
their trafficking to the cell surface (50, 51). However, in this
case, the normal folding of the protein appears to be altered,
and the trafficking defects might be due to a failure to pass the
quality check test that takes place in the endoplasmic reticu-
lum rather than due to a trafficking defect per se. Thus, it was
not astonishing that the present mutations in the NBSs in
general did not modify the insertion of the P2X3 receptor
mutants into the cell membrane of oocytes. A major change
occurred only with R295A and K299A, which were expressed
at a lower quantity, partially explaining the abolition of cur-
rent amplitudes in the voltage clamp recordings. In the case of
all other mutants, the decrease of the current response was
certainly not the consequence of a disturbed trafficking
behavior.
An inventive approach demonstrated by co-expression of
wild-type P2X3 and a mutant P2X2, where Lys-69 or -308 was
mutated to Ala, that the resulting P2X2/3 receptor functioned
normally but not when both Lys residues were mutated to Ala
(52). However, co-expression of wild-type P2X2 with a corre-
spondingly mutated P2X3 subunit (K63A or K299A) pro-
duced non-functional heteromers. Thus, the failure to rescue
function in the P2X2 subunit with both Lys residues mutated,
by wild-type P2X3, suggests that residues from two different
subunits interact in agonist binding. Similarly, the replace-
ment of two conserved residues, Lys-68 and Phe-291 (Lys-63,
Phe-280; P2X3 numbering), by cysteine led to disulfide cross-
linking between neighboring P2X1 subunits (53). Because
mutation of these residues results in a decreased ATP potency
and cysteine cross-linking is prevented in the presence of
ATP, an intersubunit ATP binding site was proposed to oper-
ate. In agreement with this idea, our P2X3 receptor model,
developed on the basis of the crystal structure of the P2X4
FIGURE 7.Model of the hP2X3 receptor. A, panel a, extracellular loop of the hP2X3 trimer. The individual subunits are labeled by different colors. Panel b,
detailed view of the supposed binding site at the interface of two neighboring subunits containing four binding segments (NBSs). Color coding of the
amino acid residues is: blue, NBS1; red, NBS2; yellow, NBS3; green, NBS4. B, NBS1–2 and NBS3–4 are located at opposite sites of a single subunit.
TABLE 1
Nucleotide binding segments of P2X receptors
Closed circle,major decrease in activity; open circle, slight decrease in activity or
change only with Ca2 imaging; h, human receptor; r, rat receptor; zf, zebrafish
receptor mutant; conserved amino acids are indicated with bold lettering.
1 Mutagenesis by alanine or cysteine with ATP or BzATP as agonists (6, 8, 44, 45).
2 Mutagenesis by alanine or cysteine with ATP as the agonist (7, 45).
3 Replacement of alanine-283 by aspartate or arginine, or replacement of all resid-
ual investigated amino acids by alanine with ,-meATP as the agonist (present
study).
4 Mutagenesis by alanine or cysteine with ATP as the agonist (39, 40, 45).
5 Prediction based on the crystal structure (18, 45).
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receptor (18), suggested in conjunction with the mutagenesis
results that NBS1–2 and NBS3–4 as a whole shape the bind-
ing pocket for ATP. These findings lend support to our previ-
ous hypothesis (19, 46) that instead of a few amino acid resi-
dues as generally believed, at least four NBSs are needed for
the docking of ATP to the P2X3 receptor. The kinetic model-
ing of the agonist-induced currents on some of the receptor
mutants suggested the involvement of AA residues (Lys-65,
Phe-174, Phe-280, Arg-281) in ligand binding, although a gat-
ing function could also be attributed to Phe-174. In accord-
ance with these results, the use of the full agonist ATP and the
partial agonist BzATP for P2X1 suggested that certain AAs of
the extracellular loop have a gating function (8). The homol-
ogy modeling of the receptor structure documented that a few
conserved AA residues, such as Thr-172, Asn-177, and Phe-
280, were in the closed state oriented away from the groove,
although their replacement with Ala caused marked changes,
suggesting that they may participate in transducting confor-
mational information changes from the binding pocket to the
ion channel. In addition, the replacement of Gly-66 by Ala
markedly depressed both the current and the [Ca2]i re-
sponses. It is quite possible that the flexible nature of this AA
would allow conformational changes to occur, as suggested
for Gly-250 in P2X1 receptors (43).
In conclusion, polypeptide clusters, rather than individual
AAs, might be responsible for agonist binding, gating, and
desensitization of P2X3 receptors.
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ATP Binding Site Mutagenesis Reveals Different Subunit
Stoichiometry of Functional P2X2/3 and P2X2/6 Receptors*□S
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Background: Heteromeric P2X receptors increase the diversity of rapid ATP signaling.
Results: Non-functional P2X2, P2X3, and P2X6 subunit mutants were used to investigate the composition of heteromeric
P2X2/3 and P2X2/6 receptors.
Conclusion: The subunit stoichiometry of P2X2/3 and P2X2/6 is 1:2 and 2:1, respectively.
Significance: Recognition sites between P2X2 and its partners rather than random association may govern the subunit com-
position of the receptor trimers.
The aim of the present experiments was to clarify the subunit
stoichiometry of P2X2/3 and P2X2/6 receptors, where the same
subunit (P2X2) forms a receptor with two different partners
(P2X3 or P2X6). For this purpose, four non-functional Ala
mutants of the P2X2, P2X3, and P2X6 subunits were generated
by replacing single, homologous amino acids particularly
important for agonist binding. Co-expression of these mutants
in HEK293 cells to yield the P2X2 WT/P2X3 mutant or P2X2
mutant/P2X3 WT receptors resulted in a selective blockade of
agonist responses in the former combination only. In contrast,
of the P2X2 WT/P2X6 mutant and P2X2 mutant/P2X6 WT
receptors, only the latter combination failed to respond to ago-
nists. The effects of ,-methylene–ATP and 2-methylthio-
ATP were determined by measuring transmembrane currents
by the patch clamp technique and intracellular Ca2 transients
by theCa2-imagingmethod. Protein labeling, purification, and
PAGE confirmed the assembly and surface trafficking of the
investigatedWTandWT/mutant combinations inXenopus lae-
vis oocytes. In conclusion, both electrophysiological and bio-
chemical investigations uniformly indicate that one subunit of
P2X2 and two subunits of P2X3 form P2X2/3 heteromeric
receptors, whereas two subunits of P2X2 and one subunit of
P2X6 constitute P2X2/6 receptors. Further, it was shown that
already two binding sites of the three possible ones are sufficient
to allow these receptors to react with their agonists.
Cys-loop, pentameric (1–3), and tetrameric (4, 5) ligand-
gated ion channels usually consist of the heteromeric composi-
tion of structurally divergent subunits. Homomeric assemblies
of identical subunits are, however, to a minor extent also pos-
sible (e.g. for the 5HT3 receptor and certain neuronal nicotinic
and GABAA receptor subtypes). More recently, an additional
ATP-gated ionotropic receptor family has been discovered by
cloning seven distinct P2X receptor subunits frommammalian
species (P2X1 to -7) (6–9). Again, P2X subunits appeared to
form not only homomeric receptor channels but also hetero-
meric ones. Original work based on co-immunoprecipitation
with epitope-tagged subunits demonstrated that only P2X6was
not able to form homooligomers, and P2X7was the only excep-
tion of constituting heterooligomeric complexes (10). Subse-
quently, it was found that P2X1/2 (11, 12), P2X1/4 (13), P2X1/5
(14), P2X2/3 (15), P2X2/6 (16), and P2X4/6 (17) receptors com-
bine the original pharmacological and biophysical properties of
their parent subunits. The huge diversity of native P2X recep-
tors and their characteristics, often differing from those of the
recombinant receptors, have been explained by the existence of
heteromeric subunit compositions (18).
Despite these findings relating to recombinant receptors and
the evidence that three subunits form both homomeric and
heteromeric P2X receptors (6, 19, 20), two further points still
need extensive clarification. First, only P2X2/3 (sensory gan-
glia) (21, 22), P2X1/5 (astrocytes) (23, 24), and probably P2X2/6
(neural stem cells) (25, 26) receptors were shown to occur
under native conditions, whereas native P2X1/2, P2X1/4, and
P2X4/6 receptors were hitherto not identified. Second, the sub-
unit stoichiometry of functional P2X2/3 receptors appears to
be 1:2 (27, 28), but for the residual heteromeric receptors, there
are no comparable data available.
In the case of the P2X2/3 receptor, two homologous amino
acid (AA)4 residues participating in agonist binding were* This work was supported by Deutsche Forschungsgemeinschaft Grant FOR
748 and the Volkswagen Foundation.
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replaced individually with alanine to yield inactive mutants of
P2X2 and P2X3 subunits; combination of the mutant P2X3
with wild-type (WT) P2X2 resulted in a non-functional recep-
tor, whereas the opposite combination was fully active (28).
Unfortunately, there were no accompanying biochemical data
presented to confirm that the functionally silent AAmutants of
P2X2 and P2X3 and their compositions with their WT coun-
terparts still exhibited undisturbed trafficking behavior and
were expressed at the cell surface.
In P2X receptors, instead of a few AA residues, four clusters
of AAs, termed nucleotide binding domains (NBD1 to -4) (29)
(here nucleotide binding segments, NBS1 to -4), were identified
as possible docking places for ATP. NBS1 and -2 appear to be
located at one subunit, whereas NBS3 and -4 are situated at the
neighboring subunit (30) in accordance with the recently
described crystal structure of the zebrafish P2X4 receptor (31).
The aim of the present experiments was to find out whether
two heteromeric receptors (P2X2/3 and P2X2/6), where P2X2
combines with two different partners, have an obligatory sub-
unit stoichiometry of 1:2 or whether the subunit stoichiometry
may be variable. For this purpose, we used the ATP structural
analogues 2-methylthio-ATP (2-MeSATP) and ,-methy-
lene–ATP (,-meATP) as well as non-functional mutants of
P2X2 and P2X3 with a single Ala mutation in NBS1 to -4 each.
Moreover, we also used homologousmutants of P2X6 to clarify
the subunit stoichiometry of the P2X2/6 receptor. Electro-
physiological measurements and Ca2 imaging as well as pro-
tein labeling, purification, and PAGE suggested that P2X2/6
receptors consist of two P2X2 subunits and one P2X6 subunit
and thereby differ from P2X2/3 receptors.
EXPERIMENTAL PROCEDURES
Culturing of HEK293 Cells—HEK293 cells were kept in Dul-
becco’s modified Eagle’s medium also containing 4.5 mg/ml
D-glucose (Invitrogen), 2 mM K-glutamine (Sigma-Aldrich),
10% fetal bovine serum (Invitrogen) at 37 °C and 10% CO2 in
humidified air.
Site-directedMutagenesis andTransfection Procedures—The
human P2X2 (hP2X2A), hP2X3 (gift of J. N. Wood, University
College, London, UK), and hP2X6 (gift of A. Surprenant, Uni-
versity of Manchester, Manchester, UK) cDNAs were sub-
cloned at PstI and EcoRI restriction sites into pIRES2-EGFP
(P2X3 andP2X6) or pIRES2-Ds-Red (P2X2) vectors fromClon-
tech for independent expression of the respective P2X subunit
and EGFP or Ds-Red, creating the pIR-P2X plasmid. All P2X
subunit mutants were generated by introducing replacement
mutations into the pIR-P2X construct using the QuikChange
site-directed mutagenesis protocol from Stratagene according
to the instruction manual. HEK293 cells were plated in plastic
dishes (electrophysiology) or onto coverslips (Ca2 imaging) 1
day before transient transfection. 0.5 g of plasmid DNA
(homomeric P2X2, P2X3, and P2X6 receptors; heteromeric
P2X2/3 and P2X2/6 receptors, 1:2 ratio) or 0.75 g of plasmid
DNA (P2X2/6 receptors, 1:4 ratio) was combined with 10 l of
PolyFect reagent from Qiagen and 100 l of Opti-MEM
(Invitrogen).
Whole-cell Patch Clamp Recordings—Whole-cell patch
clamp recordings were made after transient transfection of
HEK293 cells, at room temperature (20–22 °C), using an Axo-
patch 200B patch clamp amplifier (Molecular Devices) as
described previously (30). Transfected HEK293 cells were
searched for bymeans of a reverse differential interference con-
trast microscope with epifluorescent optics (Axiovert 100,
Zeiss). The pipette solution contained 140 mM CsCl, 1 mM
CaCl2, 2 mM MgCl2, 10 mM HEPES, and 11 mM EGTA, pH
adjusted to 7.3 using CsOH. When 2-MeSATP was used as an
agonist, GDP--S (300 M) was also included, in order to elim-
inate the negative interaction between P2Y and P2X receptors
in HEK293 cells (31). The external physiological solution con-
tained 135mMNaCl, 4.5 mMKCl, 2 mMCaCl2, 2 mMMgCl2, 10
mM HEPES, and 10 mM glucose, pH adjusted to 7.4 using
NaOH. The pipette resistances were 3–6 megaohms. Holding
potential values were corrected for the calculated liquid junc-
tion potential between the bath and pipette solution. All
recordings were made at a holding potential of 65 mV. Data
were filtered at 2 kHz with the built-in filter of the amplifier,
digitized at 5 kHz, and stored on a laboratory computer using a
Digidata 1440 interface and pClamp 10.2 software (Molecular
Devices).
Drugs were dissolved in the external solution and locally
superfused over single cells (detected by their EGFP and/or
DS-Red fluorescence), using a rapid solution change system
(SF-77B Perfusion Fast Step,Warner Instruments). Concentra-
tion-response curves were established by applying increasing
concentrations of ,-meATP or 2-MeSATP (both from Sig-
ma-Aldrich) for 2 s. The intervals between applications were
kept at 5 min throughout. Under these conditions, agonist
responses were reproducible, with the exception of those to
2-MeSATP at HEK293-P2X3 cells; the marked desensitization
at higher concentrations of 2-MeSATP (3M) was in accord-
ance with the reported long period of time required to regain
50% of control peak amplitude when determined with a paired-
pulse protocol (32) (see also supplemental Fig. 1Ac, right).
The desensitization time constants (des1 and des2) and the
recovery of P2X3 receptors from desensitization were deter-
mined as described previously (supplemental Fig. 1Ac, left) (33).
For the measurement of the recovery from desensitization,
HEK293 cells were stimulated repetitively with,-meATP (30
M; 2-s pulses) with a progressive increase in the interpulse
intervals. We measured the t50 value, which is the time needed
to regain 50% of maximally recovered currents. Only the des1
values are indicated, because the rapid phase of desensitization
appears to be the more relevant one.
Ca2 Microfluorometry—HEK293 cells were loaded 2–3
days after transient transfection, with the Ca2-sensitive fluo-
rescent dye Fura-2 acetoxymethyl ester (2.5 M; Sigma-Al-
drich) at 37 °C for 1 h in culture medium. Cells plated onto
coverslips were mounted into the superfusion chamber and
placed on the stage of an invertedmicroscope (IX-70;Olympus)
with epifluorescent optics and a cooled CCD camera (IMAGO;
Till Photonics). Throughout the experiments, cells were con-
tinuously superfused at 0.8 ml/min by means of a roller pump
with external solution. Intracellular Fura-2 was alternately
excited at 340 and 380 nm, and the emitted light was measured
at awavelength of 510 nm.TheTill Vision software (version 3.3,
Till Photonics) was used for data acquisition, system control,
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and, later, off-line analysis. The fluorescence ratio (340/380
nm) provides a relative measure of the cytosolic free Ca2 con-
centration ([Ca2]i).
For the determination of concentration-response relation-
ships, ,-meATP or 2-MeSATPwas pressure-injected locally,
bymeans of a computer-controlledDAD12 superfusion system
(ALA Scientific Instruments, Inc.). The application time was
5 s, and the intervals between two subsequent agonist applica-
tions were kept, independent of the concentration used, at 15
min. ,-meATP is a selective P2X1, P2X3, P2X1/2, P2X1/5,
and P2X2/3 receptor agonist (34), which does not activate
endogenous P2Y receptors of HEK 293 cells (35). In contrast,
2-MeSATP is a non-selective P2X/Y receptor agonist (34, 36),
which may cause an increase of [Ca2]i through the activation
of Gq protein-coupled P2Y1 receptors (35). In order to account
for this problem, concentration-response curves for 2-Me-
SATPwere constructed at HEK293 cells transfected with P2X2
subunits, P2X6 subunits, or their mutants as well as on mock-
transfected cells. [Ca2]i responses caused by 2-MeSATP after
mock transfection were subtracted from those obtained after
transfectionwith the respective subunit plasmids (Fig. 3Cb) and
yielded the [Ca2]i transients due to receptor stimulation only.
Expression of P2X2, P2X3, and P2X6 Receptors and Their
Mutants in Xenopus laevis Oocytes—Oocyte expression plas-
mids harboring the cDNAs for N-terminally hexahistidine-
tagged (His-tagged) hP2X2A, hP2X3, or hP2X6 subunit have
been described previously (12, 30). Replacementmutations or a
StrepII affinity tag-encoding sequence 5 of the stop codon
were introduced by QuikChange site-directed mutagenesis
(Stratagene). Capped cRNAs were synthesized and injected in
aliquots of 46 nl into collagenase-defolliculated X. laevis
oocytes using a Nanoliter 2000 injector (World Precision
Instruments) as described previously (37). For expression of the
heteromeric P2X2/3 receptor, cRNAs for the P2X2 and P2X3
subunit were co-injected at a 1:2 ratio (w/w). For expression of
the heteromeric P2X2/6 receptor, the cRNAs for the P2X2 and
P2X6 subunit were co-injected at a 1:4 ratio (w/w). Oocytes
were cultured at 19 °C in sterile oocyte Ringer’s solution (90mM
NaCl, 1 mM KCl, 1 mM CaCl2, 1 mMMgCl2, and 10mMHEPES,
pH 7.4) supplemented with 50 g/ml gentamycin.
Two-electrode Voltage Clamp Electrophysiology—1–2 days
after cRNA injection, current responses were evoked by 2-Me-
SATP (P2X2 and P2X2/6 receptors) or ,-meATP (P2X2/3
receptors) as indicated at ambient temperature (21–24 °C), and
recorded by conventional two-electrode voltage clamp with a
TurboTEC-05 amplifier (npi Electronics) at a holding potential
of 60 mV as described previously (37). For concentration-
response analysis, P2X receptor-mediated currents were
induced in 60-s intervals by 10-s applications of increasing con-
centrations of the indicated agonist.
Protein Labeling, Purification, and PAGE—cRNA-injected
oocytes were metabolically labeled by overnight incubation
with L-[35S]methionine (PerkinElmer Life Sciences) and, just
before protein extraction, surface-labeled with the membrane-
impermeable fluorescent dye Cy5 NHS ester (GE Healthcare)
as described previously (38). Affinity-tagged proteins were
purified by non-denaturing Ni2-NTA chromatography (Qia-
gen) or Strep-Tactin chromatography (IBA Germany) from
digitonin (1%, w/v) extracts of oocytes as indicated. The P2X
receptors were released in the non-denatured state from the
Ni2-NTA-Sepharose or the Strep-Tactin-Sepharose with elu-
tion buffer consisting of 1% (w/v) digitonin in 250 mM imida-
zole/HCl (pH 7.6) or 1% (w/v) digitonin in 0.1 M sodium phos-
phate buffer, pH 8.0, supplemented with 10 mM biotin,
respectively. Native proteins were analyzed by blue native
PAGE (BN-PAGE) as described previously (12, 39). Where
indicated, samples were treated before BN-PAGE for 1 h at
37 °C with 0.1% (w/v) SDS to induce partial dissociation of P2X
receptor complexes. To avoid quenching of the fluorescence by
the Coomassie G250 dye, BN-polyacrylamide gels were
destained prior to fluorescence imaging by repeated cycles of
incubation in 50% (v/v) acetonitrile (Biosolve) supplemented
with 25mM ammonium carbonate as described previously (40).
The destained polyacrylamide gel was repeatedly washed in 0.1
M sodium phosphate buffer, pH 8.0, and scanned wet by a
Typhoon 9410 scanner (GEHealthcare) for fluorescence detec-
tion. For the subsequent visualization of the 35S-labeled pro-
teins, the BN-polyacrylamide gels were dried, exposed to a
phosphor screen, and scanned by a PhosphorImager (Storm
820, GE Healthcare).
For reducing SDS-PAGE, proteins were denatured by incu-
bation with SDS sample buffer containing 20 mM DTT for 15
min at 56 °C and electrophoresed in parallel with 14C-labeled
molecular mass markers (Rainbow, Amersham Biosciences) on
SDS-polyacrylamide gels (10% acrylamide). SDS-polyacryl-
amide gels were scanned wet with a fluorescence scanner
(Typhoon 9410, GE Healthcare) for visualization of Cy5-la-
beled plasmamembrane-bound proteins, and thenwe dried the
gels for the subsequent detection of 35S incorporation as
described above.
The intensity of the fluorescent protein bands was quantified
using the ImageQuant TL software version 7.0 (GE Health-
care). Images of polyacrylamide gels were prepared with
ImageQuant TL for contrast adjustments. For better visibility
of weak and strong protein bands, individual lanes from the
same, but differently enhanced, ImageQuant image were
cropped and positioned using Adobe Photoshop CS4.
Microsoft PowerPoint 2003 was used for labeling. Each exper-
iment was performed at least twice with equivalent results.
Homology Modeling—We modeled, based on the published
crystal structure of the zebrafish P2X4 channel in its closed
state (31), the extracellular loop and transmembrane areas of
the hP2X2, hP2X3, and hP2X6 receptors. The software used
was Modeler 9, version 7 (41). The alignment was determined
by the align2D function, which also takes the secondary struc-
ture of the template into consideration. Homology modeling
was made with the loopmodel function with high optimization
settings. Visualization of the results was by VMD (42).
Data Analysis—Concentration-response curves for agonists
were fitted by using a three-parametric Hill plot (SigmaPlot;
SPSS). The figures show mean  S.E. values of n experiments.
One-way analysis of variance followed by the Holm-Sidak post
hoc test was used for multiple comparisons with a control
group or multiple pairwise comparisons. The differences
between two groups were evaluated by the normality test fol-
lowed by the Student’s t test or the rank sum test, as appropri-
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ate. A probability level of 0.05 or less was considered to reflect a
statistically significant difference.
RESULTS
Patch Clamp Investigations in HEK293 Cells—Alanine-scan-
ning mutagenesis in the four NBSs in hP2X3 showed that the
conserved K63A, K176A, R281A, and K299A mutants did not
react with ,-meATP (300 M) at all or responded with very
small current amplitudes only (30). The inactivity of the homol-
ogous Ala or Cys mutants in P2X1, P2X2, and P2X4 with ATP
as an agonist was demonstrated previously (see Refs. 19, 43, and
44).
Both ,-meATP and 2-MeSATP (0.3–100 M each) caused
fast inward currents at the holding potential of 65 mV (sup-
plemental Fig. 1, Aa and Ab). The current responses desensi-
tized already during the 2-s application period with a rapid
onset, which was similar both for ,-meATP and 2-MeSATP
(30 M each) (supplemental Fig. 1Ac, left). However, the recov-
ery from desensitization, which probably reflects the dissocia-
tion of the agonist from the receptor, was much slower for
2-MeSATP than for ,-meATP (30 M each) (supplemental
Fig. 1Ac, right; p 0.05). In accordance with this observation, the
Emax value of the concentration-response curve for 2-MeSATP
was smaller than that of ,-meATP (supplemental Fig. 1B; p 
0.05). At the same time, the EC50 values of the two agonists also
differed. In addition, we investigated the effect of 2-MeSATP
(10–300 M) at the mutant K176A and found that neither this
agonist nor ,-meATP (10–300 M) caused any current
response. Thus, K176A-hP2X3 was an inactive mutant irre-
spective of the type of agonist used.
In the following experiments, HEK293 cells transfected with
WT or mutant P2X2 plus P2X3 cDNA plasmids, in a ratio of
1:2, were superfused with 2-MeSATP (0.1–300 M) or ,-
meATP (0.03–300 M) for 2 s every 5 min (Fig. 1, A and B).
Although the Emax values and Hill coefficients of the concen-
tration-response curves were comparable, the EC50 values of
the two agonists differed from each other (Fig. 1, A and B, and
Table 1; the peaks of the agonist-induced currents were evalu-
ated at this stage). By keeping a 5-min interval between the
applications of increasing 2-MeSATP concentrations, there
was little desensitization within the 2-s application time (Fig.
1Aa). By contrast, with the same application protocol, ,-
meATP caused a rapid peak followed by a quasi-steady-state
response (at the end of the 2-s superfusion period; Fig. 1Ab).
Accordingly, a plot of the early peak response against the loga-
rithmic ,-meATP concentration resulted in a maximum of
the curve (Table 1), which was higher than that obtained by
plotting the late, quasi-steady-state current against the loga-
FIGURE 1. Current responses at wild-type (WT) hP2X2/3 receptors and at the combinations of mutant (mut) hP2X2 or hP2X3 subunits with their WT
partners expressed in HEK293 cells. A, whole-cell currents induced by 2-MeSATP (Aa) or ,-meATP (Ab; 0.3–100 M) were recorded with the patch clamp
technique at a holding potential of65mV. Increasing concentrations of the two agonists were locally superfused for 2 s with 5-min intervals (as indicated by
filled circlesor ahorizontal bar), and the resulting currentswere reproducedat twodifferent time scales (note thedivergent calibrationbarson the right and left).
,-meATPcauseda rapidly desensitizingearly current (e), followedbyamore constant late current (l).B, concentration-response relationships constructed for
2-MeSATP (Ba) and ,-meATP (Bb and Bc) at WT P2X2/3 receptors and their non-functional mutants, whose selected Lys and Arg residues were replaced by
Ala. The concentration-response relationships at the WT homomeric or heteromeric receptor are shown in gray. Means S.E. (error bars) of 5–8 experiments
are shown. The Hill coefficients for the respective concentration-response curves at WT P2X2/3 receptors were as follows: 1.1  0.2 (2-MeSATP); 1.1  0.1
(,-meATP, early), 1.3 0.5 (,-meATP, late). The Emax and EC50 values for the late ,-meATP concentration-response curves at WT P2X2/3 receptors were
2,365 241 pA and 5.7 2.2 M. For all further Emax and EC50 values as well as the exact number of experiments, see Table 1.
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rithmic ,-meATP concentration (Fig. 1Bb). However, the
EC50 values of the “early” (Table 1) and “late” curves (Fig. 1Bb;
p  0.05) were similar. Thus, under our experimental condi-
tions, a mixed P2X3-P2X2/3 initial response with a rapidly
desensitizing P2X3 component was followed by a slowly desen-
sitizing P2X2/3 component. It is noteworthy that the P2X2/3
currents could be investigated in isolation, when the receptor
mutants were expressed in X. laevis oocytes (no early peak cur-
rent because of strong residual desensitization at a drug-free
interval of 1 min; supplemental Fig. 2Aa).
Then we demonstrated that although 2-MeSATP and ,-
meATP equally well activated theWT P2X2/3 receptor, 2-Me-
SATP still slightly stimulated the P2X2/3 heteromeric recep-
tors containing WT P2X2 and mutant P2X3 (K63A, K176A,
R281A, and K299A), whereas ,-meATP had no effect at all at
these complexes (Fig. 1, compare Ba and Bb, and Table 1). By
contrast, whenWT P2X3 was co-transfected together with the
non-functional P2X2 mutants (K69A, K188A, R290A, and
K307A) (Fig. 1Bc, and Table 1), at positions homologous to
those targeted in the P2X3 mutants, the Emax values of ,-
meATP at all heteromeric receptors only slightly decreased,
and all EC50 values with the exception of P2X2-R290A/P2X3
did not change (Fig. 1Bc and Table 1). Thus, heteromeric
P2X2/3 receptors lost their original sensitivity toward agonists
(,-meATP) or became much less sensitive (2-MeSATP)
when the P2X3 subunits carried inactivating mutations but
were only slightly affected when the P2X2 subunits carried the
homologous mutations. These results can be explained by the
assumption that one P2X2 subunit associates with two P2X3
subunits to form a P2X2/3 heteromer.
The following experiments were designed to clarify the sub-
unit stoichiometry of P2X2/6 receptors. First of all, we trans-
fected HEK293 cells with P2X6 subunits only and did not
obtain any current response to 2-MeSATP (0.3–300 M; Fig.
2Aa). Subsequently, transfections were made by P2X2 and
P2X6 in combinations of 1:2 and 1:4. TheWTP2X2/6 receptors
at the 1:2 and 1:4 transfection ratios exhibited decreasing sen-
sitivities to 2-MeSATP; the respective Emax values gradually
decreased from the WT P2X2 to P2X2/6 (Fig. 2Aa; p  0.05
each).
The slope of the current responses measured during the last
1 s of agonist application (out of the total 2-s duration) also
differed between P2X2 and P2X2/6 (p  0.05) (e.g. at 30 M
2-MeSATP (inset to Fig. 2Ab; compare also the right panels of
Fig. 2, Ca and Cb). At 2-MeSATP concentrations higher than 3
M, there was an increasingly positive slope for the P2X2 curve
up to a concentration of 100 M, whereas the slope for the
P2X2/6 (1:4 transfection ratio) curve was negative in this
range of concentrations. The P2X2/6 (1:2 transfection ratio)
curve was found to lie between the two other ones.
Gradual acidification of the bath solution from pH 7.4 to 5.4
only slightly increased the amplitudes of the 2-MeSATP (30
M)-induced P2X2 but not P2X2/6 (1:2 transfection ratio; p
0.05) currents, whereas there was a marked potentiation of the
P2X2/6 (1:4 transfection ratio; p  0.05) current amplitudes
(Fig. 2, Ba–Bc). The sudden increase in amplitude with acidifi-
cation observed with the transfection ratio 1:4, in contrast to
the transfection ratio 1:2, may indicate that an excess of P2X6
over P2X2 is needed to generate a sufficient amount of P2X2/6
in the plasma membrane. Thus, all three experimental
approaches prove that co-transfection with P2X2 and P2X6
subunits resulted in a presumably heteromeric receptor with
functional properties differing from P2X2 only if the plasmid
cDNA ratios amounted to 1:4. Therefore, this transfection pro-
cedure was used for all subsequent investigations.
Fig. 2, Ca and Cb, shows individual concentration response
relationships for 2-MeSATP (1–300 M) at homomeric P2X2
and heteromeric P2X2/6 receptors. As previously mentioned,
the Ala replacement of four conserved AA residues in P2X2 at
positions homologous to those targeted in P2X3produced non-
functional P2X2 receptors (Fig. 2D and Table 1). When WT
P2X2 was used together with P2X6 mutants (K68A, K191A,
R287A, and K305A) for co-transfecting HEK293 cells, the Emax
and EC50 values indicated higher activity for the P2X2/P2X6-
R287A and -K305A mutants, when compared with the WT
P2X2/6 receptor, but not for the P2X2/P2X6-K68A and
-K191A mutants (Fig. 2Ea and Table 1). In contrast, the non-
functional P2X2 mutant components abolished the 2-MeATP
effects at the respective P2X2/6 receptors. The results can be
explained by the assumption that two P2X2 subunits associate
with one P2X6 subunit to form a P2X2/6 heteromer (see also
TABLE 1
Agonist sensitivities of P2X2, P2X3, P2X6, P2X2/3, and P2X2/6 recep-
tors as well as of the combinations of the respective WT and mutant
subunits expressed in HEK293 cells
Concentration-response curves for ,-meATP or 2-MeSATP were determined by
the whole-cell patch clamp method.
Receptor Agonist Emax EC50 n
pA M
P2X2WT ,-meATP 300 6
P2X3WT 4,891 85 2.1 0.1 7
P2X3-K176A 300 6
P2X2/3 WT 4,182 93a 4.1 0.4 8
P2X2/3-K63A 300 6
P2X2/3-K176A 300 6
P2X2/3-R281A 300 6
P2X2/3-K299A 300 6
P2X2-K69A/3 3,231 240b 4.5 1.4 6
P2X2-K188A/3 3,245 45b 8,4 0.4 7
P2X2-R290A/3 3,870 266 34.3 6.8b 7
P2X2-K307A/3 2,911 101b 10.3 1.2 7
P2X3WT 2-MeSATP 1,811 131a 0.9 0.3 7
P2X3-K176A 300 6
P2X2WT 6,448 29a 14.4 0.2a 10
P2X2-K69A 300 6
P2X2-K188A 300 6
P2X2-R290A 300 6
P2X2-K307A 300 7
P2X2/3 WT 4,140 139a 1.4 0.2c 6
P2X2/3-K63A 607 10b 31.7 1.4b 7
P2X2/3-K176A 1,042 32b 51.5 3.5b 8
P2X2/3-R281A 2,044 123b 31.6 5.9b 6
P2X2/3-K299A 1,042 32b 51.5 3.5b 6
P2X6WT 300 7
P2X2/6 WT 3,202 145a 30.5 3.8 10
P2X2/6-K68A 3,385 144 26.5 3.2 6
P2X2/6-K191A 3,092 93 24.3 2.0 8
P2X2/6-R287A 4,488 98b 18.2 1.1b 6
P2X2/6-K305A 4,946 131b 14.6 1.2b 7
P2X2-K69A/6 300 6
P2X2-K188A/6 300 6
P2X2-R290A/6 300 6
P2X2-K307A/6 300 6
a p 0.05; statistically significant difference from the respective values at the WT
P2X3 receptor (P2X3WT).
b p 0.05; statistically significant difference from the respective values at the WT
receptor.
c p 0.05; statistically significant difference from the respective EC50 value at the
P2X3WT receptor with ,-meATP as the agonist.
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FIGURE 2. Current responses at WT hP2X2, hP2X6, and hP2X2/6 receptors and at the combinations of the respective WT and mutant subunits
expressed inHEK293cells.A, whole-cell currents at P2X2orP2X2/6 (transfection ratios 1:2or 1:4) receptors inducedby2-MeSATP (0.1–300M)were recorded
with the patch clamp technique at a holding potential of65 mV. Increasing concentrations of the two agonists were locally superfused for 2 s with 5-min
intervals (for representative recordings and application protocol, see C). Shown are concentration-response relationships for the amplitude of the 2-MeSATP-
induced current at WT P2X2 andWT P2X2/6 receptors (see transfection ratios in parentheses). Means S.E. (error bars) of 6–10 experiments both in this panel
and in all further experiments are shown. The Hill coefficients for the respective WT receptors with 2-MeSATP as an agonist were as follows: P2X2, 1.8 0.1;
P2X2/6 (1:4 transfection), 1.2 0.1. For the Emax and EC50 values aswell as the exact number of experiments, see Table 1. The Emax and EC50 values aswell as the
Hill coefficients at theP2X2/6 receptor (1:2 transfection)wereas follows: 4,327116nA, 18.61.4M, and1.60.2 (Aa). Shownare concentration-dependent
changes of the slopes of the current responses from the beginning of the second s of application until its end (2-s applications in total; Ab). The inset shows the
amplitude and shape of two representative scaled currents in response to 2-MeSATP (30M); the slopes of the current responsesmeasured during the last 1 s
of agonist application were 0.19 0.06 pA/s for P2X2 and0.27 0.09 pA/s for P2X2/6. B, dependence of 2-MeSATP (30M)-induced current amplitudes on
a gradual decrease of the external pH value from 7.4 to 5.4 for P2X2 and P2X2/6 receptors. Shown are representative recordings (Ba and Bb) and mean
percentage changes with respect to the second current response (5-min intervals between agonist applications) at a normal pH of 7.4 (Bc). *, p  0.05;
statistically significant difference from the effect of 2-MeSATP at the P2X2 receptor. When the statistical comparison was with the predrug value of 100%, the
percentage potentiation was by 33.6 7% (P2X2; p 0.05), 16.1 11.4% (P2X2/6; transfection ratio 1:2; p 0.05), and 397.2 99.6% (P2X2/6; transfection
ratio 1:4;p0.05).C, original recordingsof current responses inducedby increasing concentrationsof 2-MeSATPatWTP2X2 (Ca) andWTP2X2/6 (Cb) receptors
(indicated by filled circles or a horizontal bar).D and E, concentration-response relationships constructed for 2-MeSATP atWT andmutant (mut) P2X2 (D) orWT
and mutant P2X2/6 (E) receptors; P2X2/6 contained either WT P2X2 and presumably non-functional mutants of P2X6 (Ea) or WT P2X6 and non-functional
mutants of P2X2 (Eb). In the non-functional mutants, selected Lys and Arg residues were replaced by Ala at homologous sites also manipulated in the P2X3
subunits (Fig. 1D). The concentration-response relationships at the WT homomeric or heteromeric receptor are gray.
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the respective oocyte voltage clamp measurements in supple-
mental Fig. 2, Da and Db).
Ca2 Imaging in HEK293 Cells—In order to lend more sup-
port to our findings, wemeasured, in addition to the transmem-
brane current responses, also the [Ca2]i transients in HEK293
cells bearing P2X2, P2X3, P2X2/3, and P2X2/6 receptors.
Whereas ,-meATP (10–300M) caused a rapidly rising and,
after its washout, also rapidly declining [Ca2]i response at
homomeric P2X3 receptors (e.g. see Fig. 3Ab, right), similar
concentrations of this agonist induced biphasic responses,
slowly recovering to base line at heteromeric P2X2/3 receptors
(Fig. 3Aa). 2-MeSATP (300 M) at the P2X2/P2X3-K63A
mutant and 2-MeSATP (10 M) at the WT P2X2/3 receptor
evoked [Ca2]i transients of practically undistinguishable
shape (Fig. 3, Aa and Ab, left). It is noteworthy that although
,-meATP is a selective P2X1, P2X3, P2X1/2, P2X1/5, and
P2X2/3 receptor agonistwithout any activity at the endogenous
P2Y receptors of HEK293 cells (see “Experimental Proce-
dures”), its EC50 value for [Ca2]i transients in HEK293 trans-
fected with WT P2X2/3 receptors was higher than that for
transmembrane currents (p 0.05; compare Figs. 1 and 3). The
Hill coefficients of the two concentration-response relation-
ships also differed from each other (p 0.05). At the moment,
we have no unequivocal explanation for these discrepancies.
However, we tentatively suggest that Ca2 influx from the
extracellular space may be slightly modified by Ca2-induced
Ca2 release from the endoplasmic reticulum and simultane-
ous sequestration of [Ca2]i by its intracellular storage sites. In
perfect agreementwith the patch clamp investigations,Ala sub-
stitutions of the relevant AAs in the P2X3 component of the
P2X2/3 receptor markedly depressed the ,-meATP (10–300
M)-induced current amplitudes (Fig. 3Ba). By contrast,
replacement of the same AAs by Ala in the P2X2 component of
this receptor complex had no major effect (Fig. 3Bb).
Because 2-MeSATP is a general P2X/P2Y receptor agonist,
the amplitudes of the 2-MeSATP (0.3–300 M)-induced
[Ca2]i transients inmock-transfectedHEK293 cells (mediated
by endogenous P2Y receptors) were subtracted from those
induced by this agonist in cells transfected with P2X2 or P2X2
plus P2X6 subunits (Fig. 3Cb, left and right panels; see “Exper-
imental Procedures”). Interestingly, this time the [Ca2]i mea-
surement yielded a lower EC50 value (p  0.05) but identical
Hill coefficient (p  0.05) of the 2-MeSATP concentration-
response curve as the corresponding values obtained by patch-
clamp recording (compare Figs. 1 and 3), a finding that also
awaits explanation.
The biphasic [Ca2]i responses appear to be typical for WT
P2X2 receptors (Fig. 3Cb, left) and heteromeric receptors con-
taining this subunit (for P2X2/6, see Fig. 3Ca). Again in agree-
ment with the patch clamp investigations, Ala substitutions of
the relevant AAs in the P2X6 component of the P2X2/6 recep-
tor had no major effect on the 2-MeSATP (10–300 M)-in-
duced [Ca2]i transients (Fig. 3Da), whereas replacement of the
homologous AAs in the P2X2 component of this receptor were
strongly inhibitory (Fig. 3Db).
Two-electrode Voltage Clamp Measurements in X. laevis
Oocytes—The subunit composition of the above homomeric
and heteromeric receptors and their expression at the cell sur-
face were investigated by biochemical methods in the non-
mammalian X. laevis oocyte expression system. Therefore, it
was important to prove that the functional data generated on
HEK293 cells and X. laevis oocytes are basically identical.
In fact, in oocytes injected with cRNAs for P2X2, P2X3, and
P2X6 receptor subunits, we made observations similar to those
described for the mammalian cell line HEK293. Non-desensi-
tizing current amplitudeswere evoked both by,-meATP and
2-MeSATP (1–300 M each) at P2X2/3 and P2X2/6 receptors,
respectively (supplemental Fig. 2, Aa and Ab). When the
P2X2/3 receptor complexes consisted of the P2X2 WT and
P2X3 mutant subunits, the ,-meATP (1–300 M) current
responses were greatly depressed (supplemental Fig. 2Ca). By
contrast, the expression of the P2X3WT subunit together with
non-functional P2X2 subunits (see Fig. 2D and supplemental
Fig. 2B for HEK293 cells and oocytes, respectively) only slightly
displaced the ,-meATP concentration-response curve of the
WT P2X2/3 receptor to the right, indicating a moderate
decrease in potency (supplemental Fig. 2Cb).
At P2X2/6 receptors, 2-MeSATP up to 300 M failed to
induce a notable current response at P2X2 mutant/P2X6 WT
heteromers (supplemental Fig. 2Db), whereas the concentra-
tion-response curves of 2-MeSATP at P2X2WT/P2X6mutant
heteromers were only modestly shifted to the left in compari-
son with those constructed at the WT P2X2/6 receptor (sup-
plemental Fig. 2Da).
A shift of the extracellular pH from 7.4 to 5.4 depressed the
Emax of the 2-MeSATP concentration-response curve from
34.0 1.1 to 25.8 0.5A (n 6 each; p 0.05) and the EC50
value from 4.6  0.5 to 3.3  0.3 M (p  0.05) but did not
change itsHill coefficient significantly. Such a decrease ofATP-
activated inward currents at rat P2X2/6 receptors by a decrease
of the external pH from 7.5 to 5.5 was described previously (16)
and appears to be valid for the oocyte expression systembut not
for HEK293 cells (see Fig. 2Bc).
Assembly and Cell Surface Trafficking of P2X2/3 and P2X2/6
Receptors—To assess the impact of the point mutations on the
assembly and cell surface expression, BN-PAGE and SDS-
PAGE analysis was performed. Like the homomeric wild type
and mutant P2X2 receptor (data not shown) and the P2X3
receptor (30), also all of the functionally impaired heteromeric
P2X2/3mutant receptorswere capable of assembling to hetero-
trimers and appearing at the cell surface (Fig. 4A, top). The
significantly larger mass of the P2X2 protomer of 72 kDa as
compared with the 55 kDa of the P2X3 protomer is reflected by
a clearly detectable retarded migration of the P2X2 protomer
and homotrimer in the BN-PAGE (Fig. 4, A and B, top) and the
SDS-PAGE (Fig. 4, A and B, bottom) gels, respectively. As
expected, the heterotrimeric assemblies of P2X2WT and P2X3
WT or P2X3 mutant subunits migrated at a lower molecular
mass than the homotrimeric P2X2 and significantly above that
of the homotrimeric P2X3 receptor, clearly indicating the for-
mation of intermediate sized heteromeric assemblies consist-
ing of P2X2 WT and P2X3 WT or P2X3 mutant subunits (Fig.
4A, top).
A physically stable interaction between P2X2WT and P2X3
WT or P2X3 mutant subunits is also apparent from a co-puri-
fication assay, in which we co-expressed the His-P2X2-StrepII
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(a protein bearing aC-terminal, nine-AAStrepII tag in addition
to the N-terminal hexahistidine tag) as a bait together withWT
or mutant His-P2X3 as the prey. Purification using metal affin-
ity chromatography or Strep-Tactin chromatography allowed
us to verify the expression of the two proteins (Fig. 4A, bottom)
and to screen for the presence of co-purified His-P2X3 protein
(Fig. 4A, bottom), respectively. His-P2X2-StrepII and WT or
mutantHis-P2X3proteins could both be isolated byNi2-NTA
chromatography from the cells in which they were co-ex-
pressed. Purification by Strep-Tactin chromatography led to
FIGURE 3. Increase of the cytosolic free Ca2 concentration ([Ca2]i) by Ca
2 influx from the extracellular space through wt-hP2X2, hP2X6, and
hP2X2/6 receptors and through the combinations of the respective WT andmutant subunits expressed in HEK293 cells. A, Ca2 imaging was carried
out on HEK293 cells loaded by the fluorescence dye Fura-2 acetoxymethyl ester. The fluorescent ratio (Fl. Ratio; FR) provides a relative measure of [Ca2]i.
Increasing concentrations of 2-MeSATP (3–300 M) were locally superfused for 5 s with 15-min intervals (as indicated by filled circles in the original recording
shown). The shape and amplitude of the individual 2-MeSATP-induced [Ca2]i transients at WT P2X2/3 receptors (Aa) can be compared with the same
parameters at the P2X2/P2X3-K63A mutant (Ab; left) and at the WT P2X3 receptor (Ab; right). B, concentration-response relationships constructed for ,-
meATP at P2X2/3 receptors containing either WT P2X2 and non-functional P2X3 subunits (Ba) or WT P2X3 and non-functional P2X2 subunits (Bb). Concentra-
tion-response curves atWTP2X2/3 receptors are also shown.C, original recording for a typical experimentwith2-MeSATP (0.3–300M) atWTP2X2/6 receptors.
The shapeandamplitudeof the individual 2-MeSATP-induced [Ca2]i transients atWTP2X2/6 receptors (Ca) canbe comparedwith the sameparameters at the
WTP2X2 receptor (Cb, bottom left) and inmock-transfected cells (Cb, top left). The 2-MeSATP-induced [Ca2]i transientsmeasured inmock-transfectedHEK293
cells were subtracted from the [Ca2]i transientsmeasured in cells transfectedwithWTP2X2 receptors to yield the concentration-response curve of 2-MeSATP
non-contaminated by the release of Ca2 from intracellular pools (Cb, right). D, concentration-response relationships constructed for 2-MeSATP at P2X2/6
receptors, which contained either WT P2X2 and presumably non-functional mutants of P2X6 (Da) or WT P2X6 and non-functional mutants of P2X2 (Db).
Concentration-response curves at WT P2X2/6 receptors are also shown. The concentration-response relationships at the WT homomeric or heteromeric
receptors are gray. Shown are mean S.E. of 19–42 experiments. The Emax and EC50 values as well as the Hill coefficients of the corrected WT concentration-
response curves were as follows: P2X2/3 and ,-meATP, 1.134 0.021, 17.2 0.9 M, and 2.5 0.2; P2X2 and 2-MeSATP, 1.099 0.072, 4.1 0.9 M, and
2.3 1.0; P2X2/6 and 2-MeSATP (1:4 transfection), 1.183 0.043, 7.4 0.9 M, and 1.5 0.2.
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the co-isolation of the non-StrepII-tagged WT or mutant His-
P2X3 proteins (Fig. 4A, bottom). When expressed alone, the
His-P2X3 was not isolated (data not shown), indicating the
absence of nonspecific binding of the His-P2X3 protein to
the Strep-Tactin resin and thus confirming the suitability of this
method for the analysis of P2X2 and P2X3 protein interaction.
Using the same biochemical techniques, we also found that
the co-expression of P2X2 mutant subunits with P2X3 WT
subunits resulted in the formation of heterotrimeric receptors,
as judged from the characteristic migration positions in the
BN-polyacrylamide gel between those of the P2X2 and P2X3
homomers (Fig. 4B, top). Also, Strep-Tactin affinity purifica-
tion of co-expressed mutant His-P2X2-StrepII proteins as bait
together with WT His-P2X3 as the prey led to the co-isolation
of the non-StrepII-tagged WT His-P2X3 proteins (Fig. 4B,
bottom).
FIGURE 4. The hP2X3 subunit co-assembles and co-purifies with the hP2X2 subunit. The indicated proteins were purified under non-denaturing condi-
tions from X. laevis oocytes by Ni2-NTA chromatography or Strep-Tactin chromatography, as indicated, resolved by BN-PAGE (top) or reducing SDS-PAGE
(bottom), and visualizedby Typhoon fluorescence scanning. Both the co-assembly of theWTHis-hP2X2-StrepII subunitwith theHis-hP2X3mutants (A) and the
His-hP2X2-StrepII mutants with the WT His-hP2X3 subunit (B) are shown. The rightmost lane designated SDS, shows P2X2/3 protein migration after partial
denaturation by a 1-h incubation with 0.1% SDS. The solid and open circles on the right indicate the numbers of hP2X2 and/or hP2X3 subunits, respectively,
incorporated in the respective protein band. Migration positions of the corresponding trimeric assemblies are indicated by arrowheads. The numbers given in
parenthesis on the right indicate themolecular masses calculated by referring to the SDS-PAGE-derivedmasses of 72 and 55 kDa for the hP2X2 and the hP2X3
protomer, respectively.
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Oocyte-expressed heteromeric P2X2/6 receptors were also
analyzed biochemically. Consistent with previous data (12), the
singly expressed P2X6 subunit could be detected in the
[35S]methionine-labeled total form (Fig. 5, A and B, inset of
bottom) but was absent at the plasma membrane (Fig. 5, A and
B, lane 1). However, upon co-expression of theWTor amutant
His-P2X6-StrepII subunit with the WT His-P2X2 subunit, a
distinct protein band was observed in the BN-polyacrylamide
gel thatmigratedwith a lowermass than that of the homomeric
P2X2 receptor (Fig. 5A, top). The reduced mass of this protein
FIGURE 5. The hP2X2 subunit coassembles and co-purifies with the hP2X6 subunit. The indicated proteins were purified under non-denaturing
conditions from X. laevis oocytes by Ni2-NTA chromatography or Strep-Tactin chromatography, as indicated, resolved by BN-PAGE (top) or reducing
SDS-PAGE (bottom), and visualized by Typhoon fluorescence scanning. The inset of the bottom panel shows the total protein forms from corresponding
lanes by [35S]methionine incorporation. Both the co-assembly of the WT His-hP2X2 subunit with the His-hP2X6-StrepII mutants (A) and the His-hP2X2
mutants with the WT His-hP2X6-StrepII subunit (B) are shown. The rightmost lane, designated SDS, shows P2X2/6 protein migration after partial
denaturation by a 1-h incubation with 0.1% SDS. The solid and open circles on the right indicate the numbers of hP2X2 and/or hP2X6 subunits,
respectively, incorporated in the respective protein band. Migration positions of the corresponding trimeric assemblies are indicated by arrowheads.
The numbers given in parenthesis on the right indicate the molecular masses calculated by referring to the SDS-PAGE-derived masses of 72 and 55 kDa
for the hP2X2 and the hP2X6 protomer, respectively.
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band can easily be reconciled with a P2X2/6 heteromer co-as-
sembled of the larger 72-kDa P2X2 subunit and the smaller
55-kDa P2X6 subunit. The presence of the P2X6 subunit in this
protein band could be demonstrated by denaturating treatment
with 0.1% SDS, which led to the dissociation into two polypep-
tides, the larger P2X2 and the smaller P2X6 subunit (Fig. 5A,
lane 9, top). The mass difference of these two polypeptides is
also apparent from dissociation of the WT P2X2/6 trimeric
protein complex in SDS-PAGE analysis (Fig. 5A, bottom).
Strep-Tactin affinity purification of co-expressed WT or
mutant His-P2X6-StrepII proteins with WT His-P2X2 as the
bait and the prey, respectively, led to the co-isolation of the
non-StrepII-tagged WT His-P2X2 protein (Fig. 5A, bottom).
Co-expression of P2X2 mutant subunits with P2X6 WT sub-
units resulted also in the formation of heterotrimeric receptors,
as evident from the characteristicmobility shift in the BN-poly-
acrylamide gel toward a lower mass (Fig. 5B, top). Also, Strep-
Tactin affinity purification of co-expressed WT His-P2X6-
StrepII proteins with mutant His-P2X2 as bait and prey,
respectively, led to the co-isolation of the non-StrepII-tagged
mutant His-P2X2 proteins (Fig. 5B, bottom).
HomologyModeling of hP2X2 Receptor and of hP2X2, hP2X3,
and hP2X6 Subunits; Schematic Representation of Subunit Stoi-
chiometry of P2X2/3 and P2X2/6 Receptors—Using the pub-
lished x-ray structure of the zebrafish P2X4 (31) as a template,
we homology-modeled the hP2X2 receptor. The individual
subunits are shown as black, dark gray, and light gray loops. The
aromatic AA residues replaced by Ala and thereby yielding
non-functional mutants are indicated in Fig. 6A; they are
located pairwise (Arg290-Lys306 and Lys69-Lys188) at two adja-
cent subunits and participate in the formation of a binding
pocket. The overlay of the P2X2, P2X3, and P2X6 subunits
shows that P2X6 does not contain the AAs forming the right
flipper of the dolphin shaping all other subunits (Fig. 6B) (19,
31). In addition, P2X6 contains a series of extra AAs between
the head and the left flipper.
A summary schematic shows our conclusions. In theory,
two subunit stoichiometries are conceivable for the P2X2/
P2X3 heterotrimer; 1:2 or 2:1 (Fig. 6C). Because our experi-
ments indicated a loss of function only in the WT P2X2/
P2X3 mutant combination (see the framed assembly in Fig.
6Ca), the 1:2 stoichiometry is compatible with the present
findings. By contrast, for the P2X2/P2X6 heterotrimer, a loss
of function was found only in the P2X2 mutant/WT P2X6
combination (see the framed assembly in Fig. 6Cb); there-
fore, in this case the combination 2:1 is compatible with the
present findings.
DISCUSSION
The three-subunit composition of homomeric and hetero-
meric P2X receptors was originally suggested on the basis of
biochemical data, including co-immunoprecipitation (6, 7) and
BN-PAGE analysis as well as chemical cross-linking of subunits
(12, 39). More recently, it was pointed out that co-immunopre-
FIGURE 6. Homology model of the P2X2 receptor and of various P2X receptor subunits; schematic representation of the subunit stoichiometry of
P2X2/3 andP2X2/6 receptors.A, binding-relevant Lys andArg residues (Arg290, Lys307, Lys69, and Lys188; P2X2numbering) of thehomomeric hP2X2 receptor.
Individual subunits are shown as black, dark gray, and light gray loops. Arg290 and Lys307 are situated at one subunit, and Lys69 and Lys188 are located at the
neighboringone. The fourAA residues are parts of oneof the three agonist bindingpouches of the P2X2 receptor.B, overlay of P2X2 (red), P2X3 (light gray), and
P2X6 (black) subunits. The right flipper of the dolphin-like structure of these subunits is missing in P2X6. C, summary schematic showing the assumed subunit
stoichiometry of (P2X2)1/(P2X3)2 (Ca) and (P2X2)2/(P2X6)1 (Cb). The experimental data obtained by co-expressingWT P2X2, P2X3, and P2X6 subunits and their
non-functional mutants with the respective subunit partners supported the above assumption.
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cipitation may not be able to differentiate between receptor
hetero-oligomers and two individual homo-oligomeric recep-
tors closely interacting in the cell membrane (for the supposed
P2X4/7 receptor, see Refs. 45 and 46). At the present time, a
wealth of data supply compelling evidence for the fact that three
subunits form a functional P2X receptor. Our experiments
were designed to investigate the subunit composition of two
neuronal heteromeric P2X receptors, composed of P2X2 and
another partner (P2X3 or P2X6).
,-meATP activates recombinant, rapidly desensitizing
P2X1 and P2X3 but not slowly desensitizing P2X2 receptors (6,
20, 34). Trinitrophenyl-ATP blocked P2X1, P2X2, and P2X2/3
receptors equally well; by contrast, diinosine pentaphosphate
inhibited P2X1 receptorswith amuchhigher affinity thanP2X3
receptors (47, 48). Eventually, the selective P2X3 antagonist
A-317491 exhibits comparable activities in blocking P2X2 and
P2X2/3 receptors (34). Thus, P2X2/3 receptors have a ligand
sensitivity resembling that of homomeric P2X3 receptors and
non-desensitizing gating characteristics resembling those of
homomeric P2X2 receptors (15, 49).
The situation with P2X2/6 receptors appears to be much
more complex. Although co-immunoprecipitation identified
P2X2 and P2X6 as possible partners for generating hetero-olig-
omeric complexes (10), and an oocyte expression study metic-
ulously searched for differences between singly injected P2X2
and co-injected P2X2 and P2X6 to yield P2X2/6 (16), most dif-
ferences were rathermodest. It was reported that, in contrast to
currents through P2X2 receptors, those through P2X2/6 recep-
tors 1) were of smaller amplitude; 2) were sometimes biphasic
and occasionally showed two phases of current decay; and 3)
exhibitedminor differences in their agonist and antagonist sen-
sitivities. However, a property that unequivocally distinguished
the two receptors was their opposite modulation by extracellu-
lar pH. Whereas P2X2 currents were increased after acidifica-
tion of the bath solution (50), P2X2/6 currents were depressed
under the same conditions (16).
It is noteworthy that only some (51) and not all groups of scien-
tists were able to detect functional homomeric P2X6 receptors in
the cell membrane (52). The reason for this discrepancymight be
that P2X6 receptors either do not pass the quality check of the
endoplasmic reticulum (53, 54), or if they do so, only in a partially
glycosylated and non-functional form (55). Further glycosylation
may result in a gain of function for some of the receptors inserted
into the plasmamembrane. These results perfectly agree with our
own findings; homomeric P2X6 receptors failed to express at the
plasmamembrane of HEK293 cells.
The first part of our study confirmed and extended the obser-
vations of North and colleagues (28) by co-expressing WT
P2X2 or WT P2X3 with the non-functional mutant counter-
parts of these subunits. In addition to the P2X3 mutants K63A
and K299A situated at neighboring receptor subunits, which
may interfere with binding as well as gating of the channel,
because their positions are adjacent to the transmembrane seg-
ments 1 and 2 forming the channel pore, two additional
mutants (K176A and R281A), being less likely to interfere with
gating, were also used in the present study. We found by utiliz-
ing both HEK293 cells and oocytes as expression systems that a
combination of the WT P2X2 with mutated P2X3 subunits
(chosen from non-functional Ala mutants introduced in any of
the four NBSs) (29) strongly inhibited or even abolished the
current response to ,-meATP, whereas the opposite combi-
nation ofWT P2X3 with mutated P2X2 subunits had very little
effect. Consistent with data published previously (28) these
results clearly demonstrate a (P2X2)1/(P2X3)2 stoichiometry of
heteromeric P2X2/3 channels, as illustrated in Fig 6Ca. As a
correlate of the cationic fluxes induced by P2X2/3 receptor
activation, [Ca2]i transients were also measured and yielded
similar data. Further, we asked ourselves whether this observa-
tionmight be true only when the P2X3-selective ,-meATP is
used (28), which occupies the agonist binding pouches between
the P2X3/P2X3 and P2X2/P2X3 subunits but most probably
not that one lying at the interface of the P2X2/P2X2 subunit
(Fig. 6 Ca). For this purpose we applied also 2-MeSATP, which
is an agonist both at homomeric P2X2 and P2X3 receptors and
therefore occupies the binding sites of any of the participating
receptor subunits. Thereby, it was possible to confirm that the
observed phenomenon is agonist-independent.
In the second part of our study, we attempted to strengthen
the hypothesis that the P2X6 subunit as a constituent of the
P2X2/6 receptor complex is able to modify the original P2X
characteristics, despite not being able to form a functional
homomeric receptor by itself. In a mammalian cell line, the
ratio of the P2X2 and P2X6 protein in P2X2/6 was either 4.1:1
or 1:2.5, depending on the ratio of the P2X2 and P2X6 plasmid
cDNAs used for transfection (1:1 and 1:4) (56). However, there
were no functional measurements accompanying this bio-
chemical and atomic forcemicroscopy investigation.We varied
the plasmid cDNA ratios of the P2X2 and P2X6 subunits in the
transfection reagent between 1:2 and 1:4 (the maximum ratio
tested by Barrera et al.) (56). Indication of the formation of
P2X2/6 heteromeric receptors with characteristics clearly dif-
ferent from those of P2X2 homomeric receptors (lower maxi-
mum current amplitude, no run-down of the current response
during a 2-s application period, marked dependence of the cur-
rent amplitude on the external pH)was found only at the higher
transfection ratio of 1:4. A combination of the WT P2X2 sub-
unit with P2X6 subunits mutated at sites homologous to those
proven to yield non-functional P2X2 and P2X3 receptors did
not alter the current response to 2-MeSATP,whereas the oppo-
site combination of WT P2X6 with mutant P2X2 subunits
resulted in non-functional receptors. Of course it cannot be
excluded that at still higher transfection ratios than used by us
(1:4), P2X2/6 receptor channels with the reverse stoichiome-
try are formed; however, the functionality of these channels still
awaits confirmation (56). In the present experiments, only
P2X2/6 channels containing a minimum of two unmutated
ATP binding sites were functional (Fig. 6Cb), as was the case
also with the P2X2/3 heteromer (Fig. 6Ca). Therefore, a
(P2X2)2/(P2X6)1 stoichiometry is the most likely one to occur.
The measurement of [Ca2]i transients caused by 2-Me-
SATP fully confirmed these results. In addition, our two-elec-
trode voltage clamp data generated inX. laevis oocytes express-
ing P2X2/6 were almost identical to those obtained in the
HEK293 system; the only difference was the opposite pH sen-
sitivity of the P2X2/6 heteromer.
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To exclude the possibility that the non-functional phenotype
of the alanine replacementmutantswithin theATPbinding site
originates fromdeficits in trimeric assembly or cell surface traf-
ficking rather than a change in agonist action, biochemical
analysis of oocytes expressing the corresponding WT and
mutant P2X receptor channels was performed. Our results
show that all mutants were capable of proper trimeric assembly
and displayed unaltered plasma membrane trafficking. This
view is further supported by the Strep-Tactin co-purification
assay, which showed that all of themutantswere able to interact
physically with the respective reciprocal WT subunit. Because
His-P2X6-StrepII subunits reached the plasmamembrane only
as integral parts of the P2X2/6 heteromer (Fig. 6, A and B, bot-
tom), affinity purification via the P2X6-StrepII subunit as bait
(and non-Strep-tagged P2X2 as the prey) enabled us to isolate
exclusively the P2X2/6 heteromer. Quantification of the rela-
tive abundance of the plasma membrane form of P2X2 and
P2X6 subunits in SDS-PAGE analysis yielded a 2:1 ratio, thus
also suggesting a (P2X2)2/(P2X6)1 stoichiometry.
The null hypothesis predicts that at a 1:1 protein expression
ratio after transfection with two different subunits, the channel
ratios for P2XA and P2XB should be 1:3:3:1 for (P2XA)3,
(P2XA)2/(P2XB)1, (P2XA)1/(P2XB)2, and (P2XB)1; these ratios
change to 1:6:12:8 and to 1:12:48:64, when the protein expres-
sion ratios are modified to 1:2 (P2X2-P2X3) and 1:4 (P2X2-
P2X6), respectively. Although we did not determine the actual
expression of the three receptor proteins, for P2X2/3 the subunit
composition generated under the conditions of the present exper-
imentswill be by the highest likelihood (P2X2)1/(P2X3)2. Both the
electrophysiological and biochemical measurements supported
the existence of this preferential subunit composition in the cell
membrane and its ability to respond to P2X agonists; the other
possible heteromerwas apparently not expressed.However, P2X2
assembled with P2X6 according to a stoichiometry of 2:1, which
was not compatible with a random process of association. Never-
theless, the only subunit combination observed in the plasma
membrane was (P2X2)2/(P2X6)1, which was also supported by
electrophysiological measurements. Hence, recognition sites
between P2X2 and its partners rather than random association
may govern the subunit composition of the receptor trimers. In
conclusion, P2X2 was a dominant subunit in the P2X2/6 hetero-
mer only, and already two binding sites of the three possible ones
were sufficient to allow P2X2/3 and P2X2/6 to react with their
agonists (also see Refs. 32, 57, and 58).
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   Although mutagenesis studies at P2X1, P2X2 and P2X4 have identified several AA 
residues, which are indispensable for agonist binding, similar information for P2X3 
receptors is rare. In the present study, we prepared cDNA-plasmids encoding 
enhanced green fluorescent protein-coupled hP2X3 subunits and transfected them 
into HEK293 cells. The cells carrying P2X3 receptors were visually identified by 
means of a differential interference contrast microscope provided with epifluorescent 
optics. These cells were whole-cell patch-clamped and the currents generated in 
response to rapid local applications of α,β-meATP were recorded as a measure of 
the agonist effect. In another series of experiments, changes in the intracellular 
concentration of free calcium ([Ca2+]i) were determined by a Ca2+-imaging setup. The 
increase of [Ca2+]i caused by α,β-meATP was due to the influx of this cation through 
the P2X3 receptor-channel. Additionally, Xenopus laevis oocytes were injected with 
cRNA for hP2X3. Current responses were again induced by α,β-meATP but 
recording was with a two-electrode voltage-clamp system. We constructed 
concentration-response curves for α,β-meATP in each of the expression system and 
compared the Emax (maximum effect) and the EC50 values (the agonist concentration 
causing 50% of Emax). Eventually, we measured the desensitization rate constants 
(τoff) of the current responses both in HEK293 cells and X. laevis oocytes in order to 
obtain information on the potentially altered desensitization rate of mutant receptors 
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in comparison with their wild-type (wt)-counterparts. Results obtained in the two 
expression systems with the three techniques used yielded basically identical results. 
Because a number of mutants failed to react to α,β-meATP, biochemical methods 
(protein labelling, purification and polyacrylamide gel chromatography) were used to 
confirm the membrane expression and trimeric structure of P2X3 receptor mutants. 
These methods proved that the failure of α,β-meATP to act at some of the mutants is 
due to a change in agonist potency rather than the missing expression of the mutant 
in the plasma membrane. 
   Mutants were generated by consecutively replacing all conserved AAs and a few 
non-conserved ones within the four NBSs of the hP2X3 subunits by the neutral Ala. 
In the first place, we confirmed our previous results relating to the critical importance 
of a few positively charged AAs (K63A, K65A, K176A, R281A, R295A, K299A). Then 
the involvement of a range of further AAs in agonist binding was also documented. 
However, we report in addition three key findings: (1) Unequivocal, although 
sometimes minor changes occurred in the amplitude of the current and/or 
intracellular Ca2+ response, when further conserved (F171, L297) or non-conserved 
(T62, F174, K284, F301) AAs were replaced by Ala, or Ala itself at the position 283 
was substituted by Asp or Arg. (2) The agonist potency decrease was additive when 
two adjacent AAs were replaced simultaneously by Ala (K65/G66, F171/T172, 
N279/F280; F280/R281) but not altered after Ala substitution of non-adjacent AAs of 
the same NBS (F171/N177). (3) The decreased current amplitude was accompanied 
in many cases by a pronounced decrease in the activation and/or desensitization rate 
of the receptor mutants (K65A, G66A, N279A). (4) All data are in complete 
agreement with the homology model of the hP2X3 receptor established on the basis 
of the crystal structure of the zebrafish P2X4 mutant. 
   The experimental and modelling data as a whole indicate that the NBSs shown to 
be involved in agonist binding were situated at opposite sites of the same subunit 
and were therefore able to form a binding pocket only at the interface of two adjacent 
subunits. Of the conserved residues investigated many were oriented toward the 
groove of the pocket, indicating that they may bind ATP directly (K63, K65, K176, 
N279, R281, R295, K299). Our experiments confirm that Ala substitution of these AA 
residues causes marked changes in the amplitude and/or gating and possibly 
desensitization kinetics of the current responses. In contrast, some of the conserved 
AA residues, such as T172, N177 and F280 were oriented away from the groove, 
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although their replacement with Ala caused pronounced changes, suggesting that 
they may participate in transducting conformational information changes from the 
binding pocket to the ion channel. The computer simulation of the agonist-induced 
currents on some of the receptor mutants by means of a hidden Markov model 
allowed to discriminate between modifications of binding or gating.  
   In conclusion, polypeptide clusters organized in NBSs, rather than individual AAs, 
might be responsible for agonist binding, gating and desensitization of P2X3 
receptors. 
 
Hausmann R, Bodnar M, Woltersdorf R, Wang H, Fuchs M, Messemer N, Qin Y, 
Gunther J, Riedel T, Grohmann M, Nieber K, Schmalzing G, Rubini P, Illes P 
(2012) ATP binding site mutagenesis reveals different subunit 
stoichiometry of functional P2X2/3 and P2X2/6 receptors. J Biol Chem 
287:13930-13943. 
 
   The present experiments were designed to investigate the subunit composition of 
two neuronal heteromeric P2X receptors, consisting of P2X2 and another partner 
(P2X3 or P2X6). As mentioned earlier, native P2X2/3 receptors occur in sensory 
ganglia, while P2X2/6 receptors were found in neural stem cells in certain phases of 
their development. We used a similar approach to that already described in our first 
publication, with the exception that EGFP-coupled P2X2 subunits were co-
transfected with Ds-Red-coupled P2X3 or P2X6 subunits. Co-transfected cells were 
identified by their mixed green-red fluorescence. The cDNA and cRNA ratios were 
kept at 1:2 for P2X2/3 and 1:4 for P2X2/6 during transfection into HEK293 cells or 
during injection into X. laevis oocytes, respectively.  
   In this study, we used a series of non-functional P2X2 and P2X3 subunit mutants, 
which failed to respond or only slightly responded to ATP or its structural analogues, 
when expressed either in HEK293 cells or in X. laevis oocytes. Individual, positively 
charged AAs were replaced sequentially in NBS1-4 by Ala (K63A, K176A, R281A, 
K299A; P2X3 numbering); homologous Ala-mutants were prepared also for P2X2 
and P2X6. In the first part of our study, we co-expressed wt-P2X2 or wt-P2X3 with 
the non-functional mutant counterparts of these subunits and found that the 
combination P2X2-wt/P2X3-mut was non-functional, whereas the combination P2X2-
mut/ P2X3-wt was fully active. These results could be confirmed, when instead of 
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α,β-meATP, 2-methylthio ATP (2-MeSATP; a non-selective P2X/P2Y receptor 
agonist) was applied. In order to achieve channel opening, at least two binding sites 
out of the three possible ones at P2X receptors have to be occupied by agonist 
molecules; therefore, we concluded that in P2X2/3 receptors 1 P2X2 subunit is 
associated with 2 P2X3 subunits. It has to be kept in mind that although α,β-meATP 
activates P2X3 and P2X2/3 receptors, only the former ones show a pronounced 
desensitization. Thus, already the agonist profile and the current pattern observed 
allows an unequivocal differentiation between P2X2 (no response to α,β-meATP, 
slow desensitization to ATP), P2X3 (α,β-meATP-sensitive, rapid desensitization to 
ATP) and P2X2/3 receptors (α,β-meATP-sensitive, slow desensitization to ATP). The 
chances to differentiate P2X2, P2X3 and P2X2/3 receptors from each other by using 
2-MeSATP are more restricted, because this agonist activates the three above 
receptor-types equally well. 
   However, 2-MeSATP had to be utilized as an agonist for P2X2, P2X6 and P2X2/6 
receptors, which are insensitive to α,β-meATP. Initially we demonstrated that P2X2/6 
receptors differ in their properties from P2X2 receptors, in that they have lower 
maximum current amplitude, show no run-down of the current response during 
prolonged agonist application, and exhibit a much stronger facilitation of the current 
amplitudes after lowering the external pH. A combination of wt-P2X2 and mut-P2X6 
subunits did not alter the effect of 2-MeSATP, whereas the opposite combination of 
wt-P2X6 with mut-P2X2 resulted in non-functional receptors. Thus, we concluded 
that in contrast to the stoichiometry of P2X2/3 in P2X2/6 2 subunits of P2X2 
associate with 1 subunit of P2X6.  
   To exclude that the non-functional phenotype of the Ala replacement mutants 
within the ATP binding site originates from deficits in trimeric assembly or cell surface 
trafficking rather than of a change in agonist action, biochemical analysis of oocytes 
expressing the corresponding wt and mutant P2X receptor channels was performed. 
Our results show that all mutants were capable of proper trimeric assembly and 
displayed unaltered plasma membrane trafficking. 
   In conclusion, electrophysiological, biochemical and homology modelling data 
unequivocally suggest that the subunit combination observed in the plasma 
membrane was (P2X2)1/(P2X3)2 on the one hand and (P2X2)2/(P2X6)1 on the other. 
Hence recognition sites between P2X2 and its partners rather than random 
association may govern the subunit composition of the receptor trimers. 
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